1
|
Bielcikova Z, Werner L, Stursa J, Cerny V, Krizova L, Spacek J, Hlousek S, Vocka M, Bartosova O, Pesta M, Kolostova K, Klezl P, Bobek V, Truksa J, Stemberkova-Hubackova S, Petruzelka L, Michalek P, Neuzil J. Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I/Ib clinical trial. Ther Adv Med Oncol 2023; 15:17588359231197957. [PMID: 37786538 PMCID: PMC10541747 DOI: 10.1177/17588359231197957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 08/03/2023] [Indexed: 10/04/2023] Open
Abstract
Mitochondrially targeted anticancer drugs (mitocans) that disrupt the energy-producing systems of cancer are emerging as new potential therapeutics. Mitochondrially targeted tamoxifen (MitoTam), an inhibitor of mitochondrial respiration respiratory complex I, is a first-in-class mitocan that was tested in the phase I/Ib MitoTam-01 trial of patients with metastatic cancer. MitoTam exhibited a manageable safety profile and efficacy; among 37% (14/38) of responders, the efficacy was greatest in patients with metastatic renal cell carcinoma (RCC) with a clinical benefit rate of 83% (5/6) of patients. This can be explained by the preferential accumulation of MitoTam in the kidney tissue in preclinical studies. Here we report the mechanism of action and safety profile of MitoTam in a case series of RCC patients. All six patients were males with a median age of 69 years, who had previously received at least three lines of palliative systemic therapy and suffered progressive disease before starting MitoTam. We recorded stable disease in four, partial response in one, and progressive disease (PD) in one patient. The histological subtype matched clear cell RCC (ccRCC) in the five responders and claro-cellular carcinoma with sarcomatoid features in the non-responder. The number of circulating tumor cells (CTCs) was evaluated longitudinally to monitor disease dynamics. Beside the decreased number of CTCs after MitoTam administration, we observed a significant decrease of the mitochondrial network mass in enriched CTCs. Two patients had long-term clinical responses to MitoTam, of 50 and 36 weeks. Both patients discontinued treatment due to adverse events, not PD. Two patients who completed the trial in November 2019 and May 2020 are still alive without subsequent anticancer therapy. The toxicity of MitoTam increased with the dosage but was manageable. The efficacy of MitoTam in pretreated ccRCC patients is linked to the novel mechanism of action of this first-in-class mitochondrially targeted drug.
Collapse
Affiliation(s)
- Zuzana Bielcikova
- Department of Oncology, General Faculty Hospital, U Nemocnice 499/2, Prague 2, 128 08, Czech Republic
| | - Lukas Werner
- Institute of Biotechnology, Czech Academy of Sciences, Prumyslova 595, Prague-West 252 50, Czech Republic Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague 4, Czech Republic
| | - Jan Stursa
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech RepublicDiabetes Centre, Institute for Clinical and Experimental Medicine, Prague 4, Czech Republic
| | - Vladimir Cerny
- Department of Radiodiagnostics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Ludmila Krizova
- Department of Oncology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Jan Spacek
- Department of Oncology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Stanislav Hlousek
- Department of Oncology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Michal Vocka
- Department of Oncology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Olga Bartosova
- Institute of Pharmacology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Michal Pesta
- Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic
| | - Katarina Kolostova
- Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Petr Klezl
- Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic Urology Clinic, Third Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Vladimir Bobek
- Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Jaroslav Truksa
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic
| | - Sona Stemberkova-Hubackova
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech RepublicDiabetes Centre, Institute for Clinical and Experimental Medicine, Prague 4, Czech Republic
| | - Lubos Petruzelka
- Department of Oncology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Pavel Michalek
- Department of Anesthesiology and Intensive Care, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Jiri Neuzil
- School of Pharmacy and Medical Science, Griffith University, Southport, Qld 4222, Australia Department of Pediatrics and Inherited Metabolic Diseases, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic Department of Physiology, Faculty of Science, Charles University, and General University Hospital, Prague, Czech Republic Institute of Biotechnology, Czech Academy of Sciences, Prumyslova 595, Prague-West 252 50, Czech Republic
| |
Collapse
|
2
|
Bielcikova Z, Stursa J, Krizova L, Dong L, Spacek J, Hlousek S, Vocka M, Rohlenova K, Bartosova O, Cerny V, Padrta T, Pesta M, Michalek P, Hubackova SS, Kolostova K, Pospisilova E, Bobek V, Klezl P, Zobalova R, Endaya B, Rohlena J, Petruzelka L, Werner L, Neuzil J. Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial. EClinicalMedicine 2023; 57:101873. [PMID: 37064512 PMCID: PMC10102891 DOI: 10.1016/j.eclinm.2023.101873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 01/10/2023] [Accepted: 01/31/2023] [Indexed: 02/25/2023] Open
Abstract
Background Mitochondria present an emerging target for cancer treatment. We have investigated the effect of mitochondrially targeted tamoxifen (MitoTam), a first-in-class anti-cancer agent, in patients with solid metastatic tumours. Methods MitoTam was tested in an open-label, single-centre (Department of Oncology, General Faculty Hospital, Charles University, Czech Republic), phase I/Ib trial in metastatic patients with various malignancies and terminated oncological therapies. In total, 75 patients were enrolled between May 23, 2018 and July 22, 2020. Phase I evaluated escalating doses of MitoTam in two therapeutic regimens using the 3 + 3 design to establish drug safety and maximum tolerated dose (MTD). In phase Ib, three dosing regimens were applied over 8 and 6 weeks to evaluate long-term toxicity of MitoTam as the primary objective and its anti-cancer effect as a secondary objective. This trial was registered with the European Medicines Agency under EudraCT 2017-004441-25. Findings In total, 37 patients were enrolled into phase I and 38 into phase Ib. In phase I, the initial application of MitoTam via peripheral vein indicated high risk of thrombophlebitis, which was avoided by central vein administration. The highest dose with acceptable side effects was 5.0 mg/kg. The prevailing adverse effects (AEs) in phase I were neutropenia (30%), anaemia (30%) and fever/hyperthermia (30%), and in phase Ib fever/hyperthermia (58%) together with anaemia (26%) and neutropenia (16%). Serious AEs were mostly related to thromboembolic (TE) complications that affected 5% and 13% of patients in phase I and Ib, respectively. The only statistically significant AE related to MitoTam treatment was anaemia in phase Ib (p = 0.004). Of the tested regimens weekly dosing with 3.0 mg/kg for 6 weeks afforded the best safety profile with almost all being grade 1 (G1) AEs. Altogether, five fatalities occurred during the study, two of them meeting criteria for Suspected Unexpected Serious Adverse Events Reporting (SUSAR) (G4 thrombocytopenia and G5 stroke). MitoTam showed benefit evaluated as clinical benefit rate (CBR) in 37% patients with the largest effect in renal cell carcinoma (RCC) where four out of six patients reached disease stabilisation (SD), one reached partial response (PR) so that in total, five out of six (83%) patients showed CBR. Interpretation In this study, the MTD was established as 5.0 mg/kg and the recommended dose of MitoTam as 3.0 mg/kg given once per week via central vein with recommended preventive anti-coagulation therapy. The prevailing toxicity included haematological AEs, hyperthermia/fever and TE complications. One fatal stroke and non-fatal G4 thrombocytopenia were recorded. MitoTam showed high efficacy against RCC. Funding Smart Brain Ltd. Translation For the Czech translation of the abstract see Supplementary Materials section.
Collapse
Affiliation(s)
- Zuzana Bielcikova
- Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
- Corresponding author. Department of Oncology, General Faculty Hospital and 1st Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague 2 128 08, Czech Republic.
| | - Jan Stursa
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
| | - Ludmila Krizova
- Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
| | - Lanfeng Dong
- School of Pharmacy and Medical Science, Griffith University, Southport, Qld 4222, Australia
| | - Jan Spacek
- Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
| | - Stanislav Hlousek
- Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
| | - Michal Vocka
- Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
| | - Katerina Rohlenova
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
| | - Olga Bartosova
- Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 128 08, Czech Republic
| | - Vladimir Cerny
- Department of Radiodiagnostics, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
| | - Tomas Padrta
- Department of Radiodiagnostics, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
| | - Michal Pesta
- Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague 121 06, Czech Republic
| | - Pavel Michalek
- Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and General University Hospital, Prague 128 08, Czech Republic
| | - Sona Stemberkova Hubackova
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
- Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague 4 140 21, Czech Republic
| | - Katarina Kolostova
- Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague 10 100 34, Czech Republic
| | - Eliska Pospisilova
- Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague 10 100 34, Czech Republic
| | - Vladimir Bobek
- Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague 10 100 34, Czech Republic
| | - Peter Klezl
- Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague 10 100 34, Czech Republic
- Urology Clinic, Third Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague 10 100 34, Czech Republic
| | - Renata Zobalova
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
| | - Berwini Endaya
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
- Department of Pediatrics and Inherited Metabolic Diseases, First Faculty of Medicine, Charles University, Prague 2 128 08, Czech Republic
| | - Jakub Rohlena
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
| | - Lubos Petruzelka
- Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic
| | - Lukas Werner
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
- Corresponding author. Institute of Biotechnology, Czech Academy of Sciences, Prumyslova 595, Prague-West 252 50, Czech Republic.
| | - Jiri Neuzil
- Institute of Biotechnology, Czech Academy of Sciences, Prague-West 252 50, Czech Republic
- School of Pharmacy and Medical Science, Griffith University, Southport, Qld 4222, Australia
- Department of Pediatrics and Inherited Metabolic Diseases, First Faculty of Medicine, Charles University, Prague 2 128 08, Czech Republic
- Department of Physiology, Faculty of Science, Charles University, Prague 2 128 00, Czech Republic
- Corresponding author. School of Pharmacy and Medical Science, Griffith University, Parklands Avenue, 4222 Southport, Qld, Australia, or Institute of Biotechnology, Czech Academy of Sciences, Prumyslova 595, Prague-West 252 50, Czech Republic.
| |
Collapse
|
3
|
Kolostova K, Pospisilova E, Matkowski R, Szelachowska J, Bobek V. Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells. Cancer Immunol Immunother 2022; 71:2901-2911. [PMID: 35471603 DOI: 10.1007/s00262-022-03189-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 03/09/2022] [Indexed: 10/18/2022]
Abstract
BACKGROUND Dendritic cell (DC) therapy counts to the promising strategies how to weaken and eradicate cancer disease. We aimed to develop a good manufacturing practice (GMP) protocol for monocyte-derived DC (Mo-DC) maturation using circulating tumor cells lysates with subsequent experimental T-cell priming in vitro. METHODS DC differentiation was induced from a population of immunomagnetically enriched CD14 + monocytes out of the leukapheresis samples (n = 6). The separation was provided automatically, in a closed bag system, using CliniMACS Prodigy® separation protocols (Miltenyi Biotec). For differentiation and maturation of CD14 + cells, DendriMACs® growing medium with supplements (GM-CSF, IL-4, IL-6, IL-1B, TNFa, PGE) was used. Immature Mo-DCs were loaded with autologous circulating tumor cell (CTCs) lysates. Autologous CTCs were sorted out by size-based filtration (MetaCell®) of the leukapheresis CD14-negative fraction. A mixture of mature Mo-DCs and autologous non-target blood cells (NTBCs) was co-cultured and the activation effect of mature Mo-DCs on T-cell activation was monitored by means of multimarker gene expression profiling. RESULTS New protocols for mMo-DC production using automatization and CTC lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation. Gene expression analysis revealed elevation for following genes in NTBC (T cells) subset primed by mMo-DCs: CD8A, CD4, MKI67, MIF, TNFA, CD86, and CD80 (p ≤ 0.01). CONCLUSION Summarizing the presented data, we might conclude mMo-DCs were generated using CliniMACS Prodigy® machine and CTC lysates in a homogenous manner showing a potential to generate NTBC activation in co-cultures. Identification of the activation signals in T-cell population by simple multimarker-qPCRs could fasten the process of effective mMo-DC production.
Collapse
Affiliation(s)
- Katarina Kolostova
- Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic
| | - Eliska Pospisilova
- Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic
| | - Rafal Matkowski
- Department of Oncology, Wrocław Medical University, Wrocław, Poland.,Breast Cancer Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, Plac Hirszfelda 12, 54-413, Wrocław, Poland
| | - Jolanta Szelachowska
- Department of Oncology, Wrocław Medical University, Wrocław, Poland.,Breast Cancer Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, Plac Hirszfelda 12, 54-413, Wrocław, Poland
| | - Vladimir Bobek
- Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic. .,3rd Department of Surgery University Hospital Motol and 1st Faculty of Medicine, Charles University, V Uvalu 84, 15006, Prague, Czech Republic. .,Department of Thoracic Surgery, Masaryk's Hospital, Krajska Zdravotni a.s., Socialni pece 3316/12A, 40113, Usti nad Labem, Czech Republic. .,Department of Thoracic Surgery, Lower Silesian Oncology, Pulmology and Hematology Center and Medical University Wroclaw, Grabiszynska 105, 53-413, Wrocław, Poland.
| |
Collapse
|
4
|
Jakabova A, Bielcikova Z, Pospisilova E, Petruzelka L, Blasiak P, Bobek V, Kolostova K. Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy. Ther Adv Med Oncol 2021; 13:17588359211028492. [PMID: 34345252 PMCID: PMC8283058 DOI: 10.1177/17588359211028492] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2021] [Accepted: 06/09/2021] [Indexed: 02/01/2023] Open
Abstract
Background and Aims: The aim of this study was to characterize circulating tumor cells (CTCs) during neoadjuvant chemotherapy (NACT) in early and locally advanced breast cancer (LABC) patients. Using ultrasound, tumor volume measurement was compared with the presence and the molecular nature of CTCs over multiple time intervals corresponding to treatment periods. Methods: A total of 20 patients diagnosed with breast cancer (BC) of different histotypes were monitored during the NACT period and in the follow-up period (~5 years). Peripheral blood for CTCs (n = 115) was taken prior to NACT, after two to three chemotherapy cycles, after the completion of NACT (before surgery) and at some time points during adjuvant therapy. CTCs were enriched using a size-based filtration method (MetaCell®) capturing viable cells, which enabled vital fluorescence microscopy. A set of tumor-associated (TA) genes and chemoresistance-associated (CA) genes was analyzed by qPCR in the enriched CTC fractions. Results: The analysis of tumor volume reduction after administration of anthracyclines (AC) and taxanes (TAX) during NACT showed that AC therapy was responsive in 60% (12/20) of tumors, whereas TAX therapy was responsive in 30% (6/20; n.s.). After NACT, CTCs were still present in 70.5% (12/17) of patients (responders versus non-responders, 61.5% versus 100%; not significant). In triple-negative BC (TNBC) patients (n = 8), tumor volume reduction was observed in 75% cases. CTCs were significantly reduced in 42.9% of all HER2-negative BC patients. In HER2+ tumors, CTC reduction was reported in 16.6% only. Relapses were also more prevalent in the HER2-positive patient group (28.5 versus 66.6%). During NACT, the presence of CTCs (three tests for each patient) identified patients with relapses and indicated significantly shorter progression-free survival (PFS) rates (p = 0.03). Differentiation between progressive disease and non-progressive disease was obtained when the occurrence of excessive expression for CA genes in CTCs was compared (p = 0.024). Absence of tumor volume reduction was also significantly indicative for progressive disease (p = 0.0224). Disseminated CTCs in HER2-negative tumors expressed HER2 in 29% of samples collected during the overall follow-up period (16/55), and in 32% of samples during the follow-up of NACT (10/31). The change accounted for 78.5% of HER2-negative patients (11/14) in total, and 63.6% of the conversion cases occurred during NACT (7/11). For the remaining four patients (36.3%), conversion to HER2+ CTCs occurred later during adjuvant therapy. We believe there is the possibility of preventing further progression by identifying less responsive tumors during NACT using CTC monitoring, which could also be used effectively during adjuvant therapy.
Collapse
Affiliation(s)
- Anna Jakabova
- Radiotherapy and Oncology Clinic, Laboratory of Personalized Medicine, University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Zuzana Bielcikova
- Department of Oncology, First Faculty of Medicine Charles University and General University Hospital in Prague, Czech Republic
| | - Eliska Pospisilova
- Radiotherapy and Oncology Clinic, Laboratory of Personalized Medicine, University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Lubos Petruzelka
- Department of Oncology, First Faculty of Medicine Charles University and General University Hospital in Prague, Czech Republic
| | - Piotr Blasiak
- Department and Clinic of Thoracic Surgery, Faculty of Medicine, Wroclaw Medical University, Wrocław, Poland
| | - Vladimir Bobek
- Radiotherapy and Oncology Clinic, Laboratory of Personalized Medicine, University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Katarina Kolostova
- Radiotherapy and Oncology Clinic, Laboratory of Personalized Medicine, University Hospital, Kralovske Vinohrady, Srobarova 50, Prague, 100 34, Czech Republic
| |
Collapse
|
5
|
Kolostova K, Pospisilova E, Pavlickova V, Bartos R, Sames M, Pawlak I, Bobek V. Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring. Am J Transl Res 2021; 13:4489-4499. [PMID: 34150029 PMCID: PMC8205800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2019] [Accepted: 06/26/2020] [Indexed: 06/12/2023]
Abstract
Treatment of aggressive glioblastoma multiforme (GBM) must be based on very precise histological and molecular diagnostic of GBM type. According to the WHO guidelines, only tissue biopsy is a relevant source of cellular material evaluated in the diagnostic process to specify the tumor features. Nevertheless, obtaining a GBM biopsy is complicated and relies mostly on resection surgery. Evaluating circulating free DNA and/or circulating tumor cells (CTCs) in the clinic, using a liquid biopsy could represent a non-invasive cancer care optimization. In the present study, the peripheral blood of patients undergoing GBM resection (n = 18) was collected and examined for CTCs. The feasibility of GBM molecular diagnostics from a simple non-invasive peripheral blood withdrawal was evaluated. The size-based enriched CTCs were analyzed using cytomorphology and their origin confirmed based on mutational analysis. In addition, shared DNA mutations in CTCs and in primary tumor tissue were searched. For the identification of CTCs, next generation sequencing (NGS) was used. The GeneReader™ sequencing platform enables targeted sequencing of a 12-gene panel and direct evaluation of detected gene variations using QIAGEN Clinical Insight Analyze (QCI-A) software with a special algorithm for liquid biopsy sequencing analysis. Herein, we present a standard operating procedure for CTC enrichment in GBM patients, CTC in vitro culture, CTC cytomorphological evaluation, and NGS analysis of CTCs using the QIAGEN Actionable Insights Tumor (ATP) Panel. CTCs were present in all tested patients (18/18). The NGS data generated for formalin-fixed paraffin-embedded (FFPE) primary tumor tissues and CTCs reached significantly high-quality parameters. The comparisons between different sample types (CTCs vs. primary tumors) and sampling area (different primary tumor regions) showed a significant level of concordance, indicating CTC testing could be used for patient monitoring and recurrence awareness. Notably, more mutations were detected when analyzing CTC samples compared with the paired primary tumors (n = 3). The results confirm the feasibility of using CTCs as a source of tumor DNA in a diagnostic process, especially when evaluating the molecular characteristics of GBMs. A major advantage of the presented NGS approach for detecting CTCs is the simultaneous identification of several markers relevant for GBM diagnostics, allowing molecular diagnostics on cytological specimens and potential administration of innovative targeted therapies.
Collapse
Affiliation(s)
- Katarina Kolostova
- Department of Personalized Medicine, University Hospital Kralovske VinohradySrobarova 50, 100 34 Prague, Czech Republic
| | - Eliska Pospisilova
- Department of Personalized Medicine, University Hospital Kralovske VinohradySrobarova 50, 100 34 Prague, Czech Republic
| | - Vladimira Pavlickova
- Department of Personalized Medicine, University Hospital Kralovske VinohradySrobarova 50, 100 34 Prague, Czech Republic
| | - Robert Bartos
- Department of Neurosurgery of The J.E. Purkinje University, Masaryk HospitalSociální péče 12A, Ústí nad Labem, 40113, Czech Republic
| | - Martin Sames
- Department of Neurosurgery of The J.E. Purkinje University, Masaryk HospitalSociální péče 12A, Ústí nad Labem, 40113, Czech Republic
| | - Ireneusz Pawlak
- Department of Thoracic Surgery, Wroclaw Medical University, Grabiszynska 105, 53-439 Wroclaw, Poland and Department of Thoracic Surgery, Lower Silesian Cancer CenterWroclaw, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland
| | - Vladimir Bobek
- Department of Personalized Medicine, University Hospital Kralovske VinohradySrobarova 50, 100 34 Prague, Czech Republic
- 3rd Department of Surgery University Hospital Motol and 1st Faculty of Medicine Charles University, V Uvalu 84, 150 06 Prague and Department of Thoracic Surgery, Masaryk’s Hospital, Krajska zdravotni a.s.Socialni pece 3316/12A, 40113 Usti nad Labem, Czech Republic
- Department of Thoracic Surgery, Wroclaw Medical University, Grabiszynska 105, 53-439 Wroclaw, Poland and Department of Thoracic Surgery, Lower Silesian Cancer CenterWroclaw, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland
| |
Collapse
|
6
|
Fialová M, Myšíková D, Laštůvka P, Licková K, Fiala J, Libánský P, Adámek S, Lischke R, Bobek V. Thyroid tumors at the limit of operability. Rozhl Chir 2020; 99:333-342. [PMID: 33032437 DOI: 10.33699/pis.2020.99.8.333-342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Comprehensive information about current thyroid carcinoma treatment options depending on its histology and extent of the disease, focusing on locally advanced findings at the limit of operability. Treatment of such a heterogeneous group requires interdisciplinary cooperation. We provide 6 unique case reports including imaging scans, description of the therapy and description of development of the condition.
Collapse
|
7
|
Klezl P, Pospisilova E, Kolostova K, Sonsky J, Maly O, Grill R, Pawlak I, Bobek V. Detection of Circulating Tumor Cells in Renal Cell Carcinoma: Disease Stage Correlation and Molecular Characterization. J Clin Med 2020; 9:jcm9051372. [PMID: 32392757 PMCID: PMC7291128 DOI: 10.3390/jcm9051372] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2020] [Revised: 04/27/2020] [Accepted: 04/28/2020] [Indexed: 12/19/2022] Open
Abstract
The presence of circulating tumor cells (CTCs) in patients with solid tumors is associated with poor prognosis. However, there are limited data concerning the detection of CTCs in renal cell cancer (RCC). The aim of this study is to evaluate the presence of CTCs in peripheral blood of patients with RCC undergoing surgery (n = 186). CTCs were tested before and after surgery as well as during the follow-up period afterwards. In total 495 CTC testing in duplicates were provided. To enrich CTCs, a size-based separation protocol and tube MetaCell® was used. CTCs presence was evaluated by single cell cytomorphology based on vital fluorescence microscopy. Additionally, to standardly applied fluorescence stains, CTCs viability was controlled by mitochondrial activity. CTCs were detected independently on the sampling order in up to 86.7% of the tested blood samples in patients undergoing RCC surgery. There is higher probability of CTC detection with growing tumor size, especially in clear cell renal cell cancer (ccRCC) cases. Similarly, the tumor size corresponds with metastasis presence and lymph node positivity and CTC detection. This paper describes for the first-time successful analysis of viable CTCs and their mitochondria as a part of the functional characterization of CTCs in RCC.
Collapse
Affiliation(s)
- Petr Klezl
- Department of Urology, University Hospital Kralovske Vinohrady, 3rd Faculty of Medicine Charles University in Prague, Srobarova 50, 10034 Prague, Czech Republic; (P.K.); (E.P.); (J.S.); (R.G.)
| | - Eliska Pospisilova
- Department of Urology, University Hospital Kralovske Vinohrady, 3rd Faculty of Medicine Charles University in Prague, Srobarova 50, 10034 Prague, Czech Republic; (P.K.); (E.P.); (J.S.); (R.G.)
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 10034 Prague, Czech Republic; (K.K.); (O.M.)
| | - Katarina Kolostova
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 10034 Prague, Czech Republic; (K.K.); (O.M.)
| | - Jindrich Sonsky
- Department of Urology, University Hospital Kralovske Vinohrady, 3rd Faculty of Medicine Charles University in Prague, Srobarova 50, 10034 Prague, Czech Republic; (P.K.); (E.P.); (J.S.); (R.G.)
| | - Ondrej Maly
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 10034 Prague, Czech Republic; (K.K.); (O.M.)
| | - Robert Grill
- Department of Urology, University Hospital Kralovske Vinohrady, 3rd Faculty of Medicine Charles University in Prague, Srobarova 50, 10034 Prague, Czech Republic; (P.K.); (E.P.); (J.S.); (R.G.)
| | - Ireneusz Pawlak
- Department of Thoracic Surgery, Lower Silesian Cancer Center, Wroclaw, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland;
| | - Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 10034 Prague, Czech Republic; (K.K.); (O.M.)
- Department of Thoracic Surgery, Lower Silesian Cancer Center, Wroclaw, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland;
- 3rd Department of Surgery University Hospital Motol, 1st Faculty of Medicine Charles University, V Uvalu 84, 150 06 Prague, Czech Republic
- Department of Histology and Embryology, Wroclaw Medical University, Wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland
- Department of Thoracic Surgery, Masaryk´s Hospital, Krajska zdravotni a.s., Socialni pece 3316/12A, 40113 Usti nad Labem, Czech Republic
- Correspondence: ; Tel.: +420-26716-31-42
| |
Collapse
|
8
|
Kiss I, Kolostova K, Pawlak I, Bobek V. Circulating tumor cells in gynaecological malignancies. J BUON 2020; 25:40-50. [PMID: 32277613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
New non-invasive approaches have developed for diagnosis and treatment of malignant diseases. Cells shed from the primary tumor circulating in the bloodstream with metastasis potential are called Circulating Tumor Cells (CTCs). These cells are easily acquired from the peripheral blood of patients, while several enrichment and isolation methods are available nowadays with different benefits and positive detection rates. A brief characterization of three major categories of detection is described (nucleic acid-based, physical properties-based, antibody-based). In this review we concentrate on gynecological malignancies and how CTCs could be used in the diagnosis of cancer, treatment management and its effective prognosis and early recurrence detection. Presence of CTCs in endometrial cancer patients show worse overall survival, while gene analysis could identify patients in need of systemic therapy after surgical treatment to prevent metastasis and recurrence. Based on the influence of human papillomavirus (HPV) in the etiology of cervical cancer, viral oncogene transcripts could be used as an ideal marker for cervical cancer cells detection. In ovarian cancer, CTCs could help in the differentiation from benign adnexal masses and show a high independence from other biomarkers such as CA125 and HE4. While detection of CTC after complete cytoreductive surgery could indicate invisible lesions, combination of tumor associated genes rises the specificity of CTC detection.
Collapse
Affiliation(s)
- Imrich Kiss
- Department of Laboratory Genetics, Laboratory Diagnostics, University Hospital Kralovske Vinohrady, Srobarova 50, Prague, Czech Republic
| | | | | | | |
Collapse
|
9
|
Pospisilova E, Kiss I, Souckova H, Tomes P, Spicka J, Matkowski R, Jedryka M, Ferrero S, Bobek V, Kolostova K. Circulating Endometrial Cells: A New Source of Information on Endometriosis Dynamics. J Clin Med 2019; 8:jcm8111938. [PMID: 31717910 PMCID: PMC6912292 DOI: 10.3390/jcm8111938] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2019] [Revised: 10/22/2019] [Accepted: 11/04/2019] [Indexed: 11/17/2022] Open
Abstract
The focus of the presented work was to isolate and characterize circulating endometrial cells (CECs) enriched from peripheral blood (PB) of patients with diagnosed endometriosis. The molecular characteristics of CECs could be supportive for an understanding of endometriosis pathogenesis and treatment decisions in the future. Material and Methods: Blood samples (n = 423) were tested for CECs presence. Subsequently, gene expression analysis (GEA) was carried out for CECs. In parallel, CECs presence and characteristics were tested during menstrual cycle (MC) phases in 11 patients. CECs were enriched by size-based separation. Results: CECs were present in 78.4% of the tested blood samples. In line with the revised American Fertility Society (rAFS) classification, CECs presence was confirmed in all the acknowledged endometriosis stages: minimal, mild, moderate, and severe. Surprisingly, CECs negativity rate was also reported for severe disease in 21.1% of cases. The CECs captured during MC phases displayed different cytomorphology, including epithelial, stromal, and stem cell-like characteristics. The highest CECs numbers were detected in the mid-secretory phase of MC, which corresponds to uterine lining decidualization. CECs captured during mid-secretory periods expressed genes KRT18, NANOG, and VIM in higher amounts when compared to the proliferative phase of MC, where genes KRT19 and ESR1 were mostly elevated. GEA of the super-positive CECs samples (1000 CECs/8 mL PB) revealed high expression of genes KRT18, VIM, NANOG, and FLT1. The expression of these genes was also elevated in the endometriosis tissue samples and endometrioma. Conclusion: The panel of the identified CEC genes could be tested in a prospective manner to confirm the role of CECs in endometriosis pathogenesis and diagnostics.
Collapse
Affiliation(s)
- Eliska Pospisilova
- Department of Laboratory Genetics, Laboratory Diagnostics, Faculty Hospital Královské Vinohrady, Srobarova 50, 100 34 Prague 10, Czech Republic (V.B.)
- Department of Gynecology, Military University Hospital and 3rd Faculty of Medicine, U Vojenske nemocnice 1200, 169 02 Prague 6, Czech Republic
| | - Imrich Kiss
- Department of Laboratory Genetics, Laboratory Diagnostics, Faculty Hospital Královské Vinohrady, Srobarova 50, 100 34 Prague 10, Czech Republic (V.B.)
- Department of Gynecology, Military University Hospital and 3rd Faculty of Medicine, U Vojenske nemocnice 1200, 169 02 Prague 6, Czech Republic
- Department of Obstetrics and Gynecology, University Hospital, Faculty of Medicine Charles University, Alej Svobody 80, 301 66 Pilsen, Czech Republic
| | - Helena Souckova
- Department of Gynecology, Military University Hospital and 3rd Faculty of Medicine, U Vojenske nemocnice 1200, 169 02 Prague 6, Czech Republic
| | - Pavel Tomes
- Department of Obstetrics and Gynecology, University Hospital, Faculty of Medicine Charles University, Alej Svobody 80, 301 66 Pilsen, Czech Republic
| | - Jan Spicka
- Department of Laboratory Genetics, Laboratory Diagnostics, Faculty Hospital Královské Vinohrady, Srobarova 50, 100 34 Prague 10, Czech Republic (V.B.)
| | - Rafal Matkowski
- Cellpeutics Sp. z o.o., Duńska 9,54-424 Wrocław, Poland
- Department of Oncology, Wroclaw Medical University, Wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland and Wroclaw Comprehensive Cancer Center, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland
| | - Marcin Jedryka
- Cellpeutics Sp. z o.o., Duńska 9,54-424 Wrocław, Poland
- Department of Oncology, Wroclaw Medical University, Wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland and Wroclaw Comprehensive Cancer Center, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland
| | - Simone Ferrero
- Academic Unit of Obstetrics and Gynecology Ospedale Policlinico San Martino Genoa, Italy Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI) University of Genoa Genoa, Italy Academic Unit of Gynecology and Obstetrics University of Genoa, 16 132 Genoa, Italy
| | - Vladimir Bobek
- Department of Laboratory Genetics, Laboratory Diagnostics, Faculty Hospital Královské Vinohrady, Srobarova 50, 100 34 Prague 10, Czech Republic (V.B.)
- Department of Oncology, Wroclaw Medical University, Wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland and Wroclaw Comprehensive Cancer Center, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland
- Department of Histology and Embryology, Wroclaw Medical University, L. Pasteur 1, 503 67 Wroclaw, Poland
- Department of Thoracic Surgery, Krajská zdravotní a.s. Hospital, 41100 Ústí nad Labem, Czech Republic
- 3rd Department of Surgery University Hospital FN Motol and 1st Faculty of Medicine Charles University, V Uvalu 84, 150 06 Prague 5, Czech Republic
| | - Katarina Kolostova
- Department of Laboratory Genetics, Laboratory Diagnostics, Faculty Hospital Královské Vinohrady, Srobarova 50, 100 34 Prague 10, Czech Republic (V.B.)
- Department of Oncology, Wroclaw Medical University, Wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland and Wroclaw Comprehensive Cancer Center, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, Poland
- Correspondence: ; Tel.: +420-267-163-142
| |
Collapse
|
10
|
Kiss I, Pospisilova E, Kolostova K, Maly V, Stanek I, Lischke R, Schutzner J, Pawlak I, Bobek V. Circulating Endometrial Cells in Women With Spontaneous Pneumothorax. Chest 2019; 157:342-355. [PMID: 31542450 DOI: 10.1016/j.chest.2019.09.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Revised: 08/23/2019] [Accepted: 09/01/2019] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The occurrence of catamenial pneumothorax (CP) is rare, and the awareness of this diagnosis among physicians is insufficient. CP is highly correlated with pelvic endometriosis and remains the most common form of thoracic endometriosis syndrome. Circulating endometrial cells (CECs) have been previously detected in patients with pelvic endometriosis. Could CECs bring new insights into pneumothorax management? METHODS This study aims to describe the occurrence and molecular characteristics of CECs in women with spontaneous pneumothorax (SP) (N = 20) with high suspicion of its catamenial character. CECs were enriched from peripheral blood by size-based separation (MetaCell). In addition to cytomorphology, gene expression profiling of captured cells was performed for 24 endometriosis-associated genes. RESULTS CECs were present in all 20 patients with SP. Enriched CECs exhibited four character features: epithelial, stem cell-like, stroma-like, and glandular. However, not all of them were present in every sampling. Gene expression profiling revealed two distinct phenotypes of CECs in SP and/or CP: one of them refers to the diaphragm openings syndrome and the other to endometrial tissue pleural implantations. Comparisons of the gene expression profiles of CECs in pneumothorax (CECs-SP group) with CECs in pelvic endometriosis (CECs-non-SP group) have revealed significantly higher expression of HER2 in the CECs-SP group compared with the CECs-non-SP group. CONCLUSIONS This proof-of-concept study demonstrates successful isolation and characterization of CECs in patients with SP. Identification of CECs in SP could alert endometriosis involvement and help early referral to gynecologic consultation for further examination and treatment.
Collapse
Affiliation(s)
- Imrich Kiss
- Department of Laboratory Genetics, Laboratory Diagnostics, Third Faculty of Medicine, Charles University Prague and University Hospital Kralovske Vinohrady, Prague, Czech Republic; Department of Gynecology, Military University Hospital and the 3rd Faculty of Medicine, Charles University, Prague, Czech Republic; 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Eliska Pospisilova
- Department of Laboratory Genetics, Laboratory Diagnostics, Third Faculty of Medicine, Charles University Prague and University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Katarina Kolostova
- Department of Laboratory Genetics, Laboratory Diagnostics, Third Faculty of Medicine, Charles University Prague and University Hospital Kralovske Vinohrady, Prague, Czech Republic; Cellpeutics Sp.z o.o., Wroclaw, Poland
| | - Vilem Maly
- Department of Thoracic Surgery, Krajska zdravotni a.s. Hospital Usti nad Labem, Czech Republic
| | - Ivan Stanek
- Department of Thoracic Surgery, Krajska zdravotni a.s. Hospital Usti nad Labem, Czech Republic
| | - Robert Lischke
- 3rd Department of Surgery, University Hospital FN Motol and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Jan Schutzner
- 3rd Department of Surgery, University Hospital FN Motol and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Ireneusz Pawlak
- Department of Thoracic Surgery, Lower Silesian Oncology Centre, Wroclaw, Poland
| | - Vladimir Bobek
- Department of Laboratory Genetics, Laboratory Diagnostics, Third Faculty of Medicine, Charles University Prague and University Hospital Kralovske Vinohrady, Prague, Czech Republic; Cellpeutics Sp.z o.o., Wroclaw, Poland; Department of Thoracic Surgery, Krajska zdravotni a.s. Hospital Usti nad Labem, Czech Republic; 3rd Department of Surgery, University Hospital FN Motol and 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland; Department of Thoracic Surgery, Lower Silesian Oncology Centre, Wroclaw, Poland.
| |
Collapse
|
11
|
Maly V, Maly O, Kolostova K, Bobek V. Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer. In Vivo 2019; 33:1027-1037. [PMID: 31280190 PMCID: PMC6689346 DOI: 10.21873/invivo.11571] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 05/11/2019] [Accepted: 05/13/2019] [Indexed: 02/06/2023]
Abstract
Circulating tumor cells (CTCs), detached from the primary tumor or metastases and shed in the patient's bloodstream, represent a relatively easily obtainable sample of the cancer tissue that can indicate the actual state of cancer, and their evaluation can be repeated many times during the course of treatment. As part of liquid biopsy, evaluation of CTCs provides a lot of clinically relevant information, which reflects the actual, real-time conditions of the disease. CTCs can be used in cancer diagnosis or screening, real-time long-term disease monitoring and even therapy guidance. Their analysis can include their number, morphology, and biological features by using immunocytochemistry and all "-omic" technologies. This review describes methods of CTC isolation and potential clinical utilization in lung cancer.
Collapse
Affiliation(s)
- Vilem Maly
- Department of Laboratory Genetics, Laboratory Diagnostics, University Hospital Kralovske Vinohrady, Prague, Czech Republic
- Department of Thoracic Surgery, Krajska Zdravotni a.s. Hospital, Usti nad Labem, Czech Republic
| | - Ondrej Maly
- Department of Laboratory Genetics, Laboratory Diagnostics, University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Katarina Kolostova
- Department of Laboratory Genetics, Laboratory Diagnostics, University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Vladimir Bobek
- Department of Laboratory Genetics, Laboratory Diagnostics, University Hospital Kralovske Vinohrady, Prague, Czech Republic
- Department of Thoracic Surgery, Krajska Zdravotni a.s. Hospital, Usti nad Labem, Czech Republic
- Department of Thoracic Surgery, Lower Silesian Oncology Centre, Wroclaw, Poland
- 3rd Department of Surgery, University Hospital FN Motol and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
| |
Collapse
|
12
|
Grill R, Kolostova K, Klezl P, Sonsky J, Bobek V. [68] Presence of viable circulating tumour cells in kidney cancer. Arab J Urol 2018. [DOI: 10.1016/j.aju.2018.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- Robert Grill
- Urology Clinic, 3rd Faculty of Medicine Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Katarina Kolostova
- Centre of Applied Bioimplantology, 3rd Faculty of Medicine Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Petr Klezl
- Urology Clinic, 3rd Faculty of Medicine Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Jinich Sonsky
- Urology Clinic, 3rd Faculty of Medicine Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Vladimir Bobek
- Centre of Applied Bioimplantology, 3rd Faculty of Medicine Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| |
Collapse
|
13
|
Kolostova K, Rzechonek A, Schützner J, Grill R, Lischke R, Hladik P, Simonek J, Bobek V. Circulating Tumor Cells as an Auxiliary Diagnostic Tool in Surgery. ACTA ACUST UNITED AC 2018; 31:1197-1202. [PMID: 29102946 DOI: 10.21873/invivo.11190] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Revised: 08/21/2017] [Accepted: 09/04/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND In general, the presence of circulating tumor cells (CTCs) in peripheral blood (PB) is associated with a relative shorter overall survival in cancer patients. The clinical utility of CTC diagnostics is changing: from prognostic test to an assay predicting therapy response, enabling the right choice of therapy and monitoring the effect of administered therapy. We present two case reports of patients with suspicion of lung and pancreatic cancer, without obtainable preoperative biopsy for histological verification. The focus of the presented study was not to deliver a complete tumor tissue classification to the surgeon, but to answer the question if there is malignant disease or not. The results are based on CTC presence and characterization. MATERIALS AND METHODS A size-based separation method for viable CTC enrichment from anticoagulated PB was used. The separated cells were cytomorphologically examined using vital fluorescent microscopy. Additionally, to confirm the epithelial origin of the cells on the separation membrane, CTC gene expression analysis was performed. RESULTS CTCs were successfully enriched and cultured in vitro in both tested samples. The epithelial character of the captured cells was confirmed by quantitative-polymerase chain reaction (qPCR) analysis for a set of tumor-associated genes. CONCLUSION Detection of cancer cells in PB (liquid biopsy) and their molecular characterization could significantly help complete the tumor diagnostic process in a time-efficient manner.
Collapse
Affiliation(s)
- Katarina Kolostova
- Department of Laboratory Genetics, Kralovske Vinohrady University Hospital, Prague, Czech Republic
| | - Adam Rzechonek
- Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
| | - Jan Schützner
- Third Department of Surgery, First Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic
| | - Robert Grill
- Department of Laboratory Genetics, Kralovske Vinohrady University Hospital, Prague, Czech Republic
| | - Robert Lischke
- Third Department of Surgery, First Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic
| | - Pavel Hladik
- Third Department of Surgery, First Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic
| | - Jan Simonek
- Third Department of Surgery, First Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic
| | - Vladimir Bobek
- Department of Laboratory Genetics, Kralovske Vinohrady University Hospital, Prague, Czech Republic .,Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland.,Third Department of Surgery, First Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic.,Department of Thoracic Surgery, Masaryk's Hospital in Ustinad Labem, Labem, Czech Republic
| |
Collapse
|
14
|
Kiss I, Kolostova K, Matkowski R, Jędryka M, Czekański A, Pavlasek J, Bobek V. Correlation Between Disease Stage and the Presence of Viable Circulating Tumor Cells in Endometrial Cancer. Anticancer Res 2018; 38:2983-2987. [PMID: 29715128 DOI: 10.21873/anticanres.12550] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Revised: 04/01/2018] [Accepted: 04/02/2018] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM The presence of circulating tumor cells (CTCs) in the peripheral blood of patients with solid tumors is associated with a poor prognosis. However, there are limited data concerning the detection of CTCs in endometrial cancer (EC). The aim of this study was to evaluate the presence of CTCs in the peripheral blood of patients with EC. MATERIALS AND METHODS Peripheral blood samples from 92 patients who underwent a surgical procedure were evaluated using MetaCell® separation technology for CTCs. RESULTS CTCs were detected in 69 (75%) patients with EC. CONCLUSION CTCs were detected in a higher percentage of patients than in other studies. The results showed that the technology applied in this study can efficiently capture viable tumor cells in the blood that can be cultured while maintaining their original phenotype. This paper discusses the first successful culturing of human circulating endometrial cancer cells for further downstream functional and molecular characterization.
Collapse
Affiliation(s)
- Imrich Kiss
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic.,Department of Gynecology, Military University Hospital and 3 Faculty of Medicine Charles University, Prague, Czech Republic
| | - Katarina Kolostova
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Rafał Matkowski
- Division of Surgical Oncology, Gynaecological Oncology and Department of Oncology, Lower Silesian Cancer Center and Wroclaw Medical University, Wroclaw, Poland
| | - Marcin Jędryka
- Division of Surgical Oncology, Gynaecological Oncology and Department of Oncology, Lower Silesian Cancer Center and Wroclaw Medical University, Wroclaw, Poland
| | - Andrzej Czekański
- Division of Surgical Oncology, Gynaecological Oncology and Department of Oncology, Lower Silesian Cancer Center and Wroclaw Medical University, Wroclaw, Poland
| | - Jiri Pavlasek
- Department of Obstetrics and Gynecology, Hospital Liberec, Liberec, Czech Republic
| | - Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic .,3rd Department of Surgery University Hospital Motol and 1st Faculty of Medicine Charles University, Prague, Czech Republic.,Department of Thoracic Surgery, Masaryk's Hospital, Usti nad Labem, Czech Republic.,Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland.,Department of Thoracic Surgery, Lower Silesian Cancer Center, Wroclaw, Poland
| |
Collapse
|
15
|
Eliasova P, Pinkas M, Kolostova K, Gurlich R, Bobek V. Circulating tumor cells in different stages of colorectal cancer. Folia Histochem Cytobiol 2018; 55:1-5. [PMID: 28509310 DOI: 10.5603/fhc.a2017.0005] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Revised: 01/01/2017] [Accepted: 04/19/2017] [Indexed: 12/30/2022] Open
Abstract
INTRODUCTION Liquid biopsies are noninvasive tests using blood or body fluids to detect circulating tumor cells (CTCs) or the products of tumor cells, such as fragments of nucleic acids or proteins that are shed into biological fluids from primary tumor or its metastates. The analysis of published clinical studies provides coherent evidence that the presence of CTCs detected in peripheral blood is a strong prognostic factor in patients with colorectal carcinoma (CRC). The aim of the study was to implement size-based separation protocol of CTCs in CRC patients. MATERIAL AND METHODS Patients diagnosed with different stages of CRC (n = 98) were included in the study. All patients have been diagnosed for colorectal adenocarcinoma by pathology examination, 45 patients with colon carcinoma and 53 with rectosigmoid cancer. A size-based separation method (MetaCell®) for viable CTC enrichment from peripheral blood was used to assess the presence of CTCs by cytomorphological evaluation using vital fluorescence microscopy. RESULTS Cytomorphological analysis revealed that 81 (83%) tested samples were CTC-positive and 17 (17%) were CTC-negative. We report a successful isolation of CTCs with proliferation potential in patients with CRC. The CTCs were cultured in vitro for further downstream applications. Some of the isolated CTCs were able to grow in vitro for 6 months as a standard cell culture. CONCLUSIONS We established a reliable, inexpensive and relatively fast protocol for CTCs enrichment in CRC patients by means of vital fluorescence staining which enables their further analysis in vitro.
Collapse
Affiliation(s)
| | | | | | | | - Vladimir Bobek
- University Hospital Kralovske Vinohrady Department of Laboratory Genetics, Srobarova 50, 100 34, Prague, Czech Republic.
| |
Collapse
|
16
|
Bobek V, Kiss I, Maly V, Lischke R, Schutzner J, Stanek I, Kolostova K. P-115CIRCULATING ENDOMETRIAL CELLS: NEW TOOLS FOR DIAGNOSIS OF PNEUMOTHORAX IN PATIENTS WITH INAPPARENT ENDOMETRIOSIS. Interact Cardiovasc Thorac Surg 2017. [DOI: 10.1093/icvts/ivx280.115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Cegan M, Kobierzycki C, Kolostova K, Kiss I, Bobek V, Grill R. Circulating tumor cells in urological cancers. Folia Histochem Cytobiol 2017; 55:107-113. [PMID: 28994093 DOI: 10.5603/fhc.a2017.0015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2016] [Revised: 04/13/2017] [Accepted: 09/18/2017] [Indexed: 11/25/2022] Open
Abstract
Circulating tumor cells (CTC) represent a very small subpopulation of the cancer cells found in the bloodstream of patients in the metastatic phase of neoplastic disease. Due to the timeline of the disease, they are regarded as a negative prognostic marker. This study focused on determining CTC percentages; these values vary be-tween different types of cancer. In addition to their diagnostic use, CTCs may also be used to treat the disease. Calculating CTC population size and analyzing their biology in patients in advanced stages of cancer may prove valuable in creating a molecular profile for the disease. This would strongly encourage diagnostics and enable personalized treatment. We here present an analysis of recent data on CTCs in urological cancers and their potential uses.
Collapse
Affiliation(s)
| | | | | | | | - Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic; Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland; 3rd Department of Surgery, Motol University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
| | | |
Collapse
|
18
|
Jakabova A, Bielcikova Z, Pospisilova E, Matkowski R, Szynglarewicz B, Staszek-Szewczyk U, Zemanova M, Petruzelka L, Eliasova P, Kolostova K, Bobek V. Molecular characterization and heterogeneity of circulating tumor cells in breast cancer. Breast Cancer Res Treat 2017; 166:695-700. [PMID: 28815327 PMCID: PMC5680374 DOI: 10.1007/s10549-017-4452-9] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2017] [Accepted: 08/07/2017] [Indexed: 12/19/2022]
Abstract
Introduction This study analyzes peripheral blood samples from breast cancer (BC) patients. CTCs from peripheral blood were enriched by size-based separation and were then cultivated in vitro. The primary aim of this study was to demonstrate the antigen independent CTC separation method with high CTC recovery. Subsequently, CTCs enriched several times during the treatment were characterized molecularly. Methods Patients with different stages of BC (N = 167) were included into the study. All patients were candidates for surgery, surgical diagnostics, or were undergoing chemotherapy. In parallel, 20 patients were monitored regularly and in addition to CTC presence, also CTC character was examined by qPCR, with special focus on HER2 and ESR status. Results CTC positivity in the cohort was 76%. There was no significant difference between the tested groups, but the highest CTC occurrence was identified in the group undergoing surgery and similarly in the group before the start of neoadjuvant treatment. On the other hand, the lowest CTC frequencies were observed in the menopausal patient group (56%), ESR+ patient group (60%), and DCIS group (44.4%). It is worth noting that after completion of neoadjuvant therapy (NACT) CTCs were present in 77.7% of cases. On the other hand, patients under hormonal treatment were CTC positive only in 52% of cases. Discussions Interestingly, HER2 and ESR status of CTCs differs from the status of primary tumor. In 50% of patients HER2 status on CTCs changed not only from HER2+ to HER2−, but also from HER2– to HER2+ (33%). ESR status in CTCs changed only in one direction from ESR+ to ESR−. Conclusions Data obtained from the present study suggest that BC is a heterogeneous disease but CTCs may be detected independently of the disease characteristics in 76% of patients at any time point during the course of the disease. This relatively high CTC occurrence in BC should be considered when planning the long-term patient monitoring.
Collapse
Affiliation(s)
- Anna Jakabova
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague, Czech Republic
| | - Zuzana Bielcikova
- Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Eliska Pospisilova
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague, Czech Republic
| | - Rafal Matkowski
- Division of Surgical Oncology and Department of Oncology, Wroclaw Medical University, Wybrzeże Ludwika Pasteura 1, 50-367, Wrocław, Poland.,Breast Unit, Lower Silesian Cancer Center, Wroclaw, Plac Hirszfelda 12, 53-413, Wrocław, Poland
| | - Bartlomiej Szynglarewicz
- Division of Surgical Oncology and Department of Oncology, Wroclaw Medical University, Wybrzeże Ludwika Pasteura 1, 50-367, Wrocław, Poland.,Breast Unit, Lower Silesian Cancer Center, Wroclaw, Plac Hirszfelda 12, 53-413, Wrocław, Poland
| | - Urszula Staszek-Szewczyk
- Division of Surgical Oncology and Department of Oncology, Wroclaw Medical University, Wybrzeże Ludwika Pasteura 1, 50-367, Wrocław, Poland.,Breast Unit, Lower Silesian Cancer Center, Wroclaw, Plac Hirszfelda 12, 53-413, Wrocław, Poland
| | - Milada Zemanova
- Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Lubos Petruzelka
- Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Petra Eliasova
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague, Czech Republic
| | - Katarina Kolostova
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague, Czech Republic
| | - Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague, Czech Republic. .,Department of Surgery, University Hospital Motol, V Uvalu 84, 150 06, Prague, Czech Republic. .,Faculty of Medicine, Charles University, V Uvalu 84, 150 06, Prague, Czech Republic. .,Department of Thoracic Surgery, Masaryk´s Hospital, Krajska zdravotni a.s., Socialni pece 3316/12A, 40113, Usti Nad Labem, Czech Republic. .,Department of Histology and Embryology, Wroclaw Medical University, Wybrzeże Ludwika Pasteura 1, 50-367, Wrocław, Poland.
| |
Collapse
|
19
|
Schützner J, Šimonek J, Stolz A, Kolařík J, Pozniak J, Bobek V, Pafko P, Lischke R. [Ruptures of the diaphragm]. Rozhl Chir 2017; 96:493-497. [PMID: 29320210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
INTRODUCTION The diaphragm is a flat muscle that divides the thoracic and abdominal cavities, and it is one of the most important muscles involved in respiration. Traumas of the diaphragm include its rupture caused by an external force, resulting in blunt or penetrating injuries. Diaphragmatic rupture is associated with the risk of a prolapse (i.e. not a typical hernia) of abdominal organs into the pleural cavity. The rupture may occur due to a blunt injury of the chest or abdomen, or due to penetrating injuries (gunshots, stab wounds, foreign bodies) in the lower part of the chest and epigastrium. Ruptures never heal spontaneously and always require suture of the diaphragmatic defect. Most acute rupture cases are managed using laparotomy; thoracotomy is preferred for lately recognised ruptures to facilitate the removal of adhesions in the thoracic cavity developed between the diaphragmatic defect and a lung. Thirty one patients with diaphragmatic rupture were operated at the 3rd Department of Surgery of the 1st Faculty of Medicine, Charles University and University Hospital Motol between 2006 and 2016. Acute rupture was present in 60% of the cases and chronic in 40%. Right-sided rupture was found in 20% and left-sided in 80%. CONCLUSION The authors describe surgical treatment of diaphragmatic ruptures. They recommend an early surgical treatment if diaphragmatic rupture is recognized. Generally, the prognosis of the patients depends on availability of professional health care; ideally, these patients should be treated at specialised traumacentres with specialists for abdominal and thoracic surgery. The authors advise against establishing injudicious thoracic drainage in cases where diaphragmatic rupture with herniation of abdominal organs into the thorax may be present.Key words: polytrauma - acute rupture of diaphragm - chronic rupture - suture - patch.
Collapse
|
20
|
Kolostova K, Pinkas M, Jakabova A, Pospisilova E, Svobodova P, Spicka J, Cegan M, Matkowski R, Bobek V. Molecular characterization of circulating tumor cells in ovarian cancer. Am J Cancer Res 2016; 6:973-980. [PMID: 27293992 PMCID: PMC4889713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Accepted: 03/13/2016] [Indexed: 06/06/2023] Open
Abstract
The main focus of the study was to detect circulating tumor cells (CTCs) in ovarian cancer (OC) patients using a new methodological approach (MetaCell(TM)) which is based on size-dependent separation of CTCs and subsequent cytomorphological evaluation. Cytomorphological evaluation using vital fluorescence microscopy approach enables to use the captured cells for further RNA/DNA analysis. The cytomorphological analysis is then completed by gene expression analysis (GEA). GEA showed that relative expression of EPCAM is elevated in CTC-enriched fractions in comparison to the whole peripheral blood sample and that the expression grows with in vitro cultivation time. Comparison of the relative gene expression level in the group of peripheral blood samples and CTC-fraction samples confirmed a statistically significant difference for the following genes (p < 0.02): KRT7, WT1, EPCAM, MUC16, MUC1, KRT18 and KRT19. Thus, we suggest that the combination of the above listed genes could confirm CTCs presence in OC patients with higher specificity than when GEA tests are performed for one marker only. The GEA revealed two separate clusters identifying patients with or without CTCs.
Collapse
Affiliation(s)
- Katarina Kolostova
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 10034 Prague, Czech Republic
| | - Michael Pinkas
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 10034 Prague, Czech Republic
| | - Anna Jakabova
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 10034 Prague, Czech Republic
| | - Eliska Pospisilova
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 10034 Prague, Czech Republic
| | - Pavla Svobodova
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 10034 Prague, Czech Republic
| | - Jan Spicka
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 10034 Prague, Czech Republic
| | - Martin Cegan
- Department of Pathology and Thoracic Surgery, Masaryk’s Hospital in Usti nad LabemKrajska zdravotni a.s., Socialni pece 3316/12A, 40113 Usti nad Labem, Czech Republic
| | - Rafal Matkowski
- Division of Surgical Oncology, Gynaecological Oncology, Chemotherapy and Department of Oncology, Wroclaw Medical Universitywybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland
- Lower Silesian Cancer CenterWroclaw, Plac Hirszfelda 12, 53-413 Wrocław, Poland
| | - Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 10034 Prague, Czech Republic
- Department of Pathology and Thoracic Surgery, Masaryk’s Hospital in Usti nad LabemKrajska zdravotni a.s., Socialni pece 3316/12A, 40113 Usti nad Labem, Czech Republic
- Department of Histology and Embryology, Wroclaw Medical Universitywybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland
- 3 Department of Surgery University Hospital Motol and 1 Faculty of Medicine Charles UniversityV Uvalu 84, 15006 Prague, Czech Republic
| |
Collapse
|
21
|
Rzechonek A, Cygan M, Blasiak P, Muszczynska-Bernhard B, Bobek V, Lubicz M, Adamiak J. Expression of Ceramide Galactosyltransferase (UGT8) in Primary and Metastatic Lung Tissues of Non-Small-Cell Lung Cancer. Adv Exp Med Biol 2016; 952:51-58. [PMID: 27620310 DOI: 10.1007/5584_2016_69] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Ceramide galactosyltransferase (UGT8) is an enzyme that regulates the synthesis of sphingolipids of the myelin sheath in nervous systems. The protein raises an increasing research interest as a potential marker of cancer progression in various organs. In the present study we seek to determine whether UGT8 could play a role of a therapeutic marker in non-small cell lung carcinoma (NSCLC). We addressed the issue by examining the intensity of UGT8 expression in tissue specimens of primary and corresponding metastatic lung tumors in 19 NSCLC patients undergoing surgery. The methodology was one of immunohistochemical tissue staining using light microscopy. The findings were that the majority of both lung primary and metastatic tumor tissues were positive in UGT8 signals. The cytoplasmic expression of UGT8 was found in 68.4 % of cases of primary tumors and 82.2 % of metastases, with a positive correlation between the UGT8 expression in both tumor tissues. The normal tissue adjacent to tumors showed no positive UGT8 staining. However, we failed to find any appreciable difference in UGT8 expression depending on the clinical stage of NSCLC or lymph node involvement. Nor was there any association between UGT8 expression in tumor tissues and patients' survival time. We conclude that it is unlikely that therapeutic targeting of UGT8 could inhibit cell proliferation and invasion of NSCLC. UGT8, although enhanced in NSCLC tissues, does not meet the criteria of a lung tumor marker. Thus, UGT8 cannot be considered as having diagnostic or therapeutic utility in NSCLC. The pathophysiological meaning of enhanced expression of UGT8 in lung cancer remains to be explored in further studies.
Collapse
Affiliation(s)
- Adam Rzechonek
- Department of Thoracic Surgery, Wroclaw Medical University, 105 Grabiszynska Street, 53-439, Wroclaw, Poland.
| | - Martin Cygan
- Krajská zdravotní, a.s., Ústí nad Labem Sociální péče 3316/12A, Ústí nad Labem, Czech Republic
| | - Piotr Blasiak
- Department of Pathology, Lower Silesian Center of Lung Diseases, 105 Grabiszynska Street, 53-439, Wroclaw, Poland
| | - Beata Muszczynska-Bernhard
- Department of Pathology, Lower Silesian Center of Lung Diseases, 105 Grabiszynska Street, 53-439, Wroclaw, Poland
| | - Vladimir Bobek
- Department of Tumor Biology and Department of Surgery, Third Faculty of Medicine, Charles University Prague, Prague, Czech Republic
| | - Marek Lubicz
- Department of Computer Science and Management, Wroclaw University of Technology, 37 Wybrzeze Wyspianskiego Street, 50-370, Wroclaw, Poland
| | - Jaroslaw Adamiak
- Department of Pathology, Lower Silesian Center of Lung Diseases, 105 Grabiszynska Street, 53-439, Wroclaw, Poland
| |
Collapse
|
22
|
Schützner J, Šimonek J, Stolz A, Kolařík J, Pozniak J, Bobek V, Pafko P, Lischke R. [Development of tracheal resection technique - our experience]. Rozhl Chir 2016; 95:19-24. [PMID: 26982188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
INTRODUCTION Tracheal resections are very frequent interventions on the trachea in general. In borderline cases where the tracheal resection length is too high, the situation can be resolved by inserting a stent or Montgomerys T cannula. Tracheal stenoses are of benign origin in 94%, and malignant in 6% of cases. We present a summary of tracheal resection interventions for the last 21 years. METHOD 235 tracheal resections were performed at the authors institution in 1993-2013. In total 221 benign stenosis cases (85 % developed after tracheostomy, 15% developed after intubation) and 14 malignant cases were treated. The patients were divided into two groups: A resection in years 19932002 and B - resection in years 20032013. The comparison of these two time periods is presented with focus on surgical procedures development and recommendations based on experienced complications. RESULTS Restenosis (early or late) is the most common complication during the process of tracheal resection treatment. Tiny fistulas in the suture can be diagnosed easily by minor air leaking and are treated conservatively without intervention. Fortunately, suture insufficiency is relatively rare. In some cases the restenoses can be resected or treated by stent application or by Montgomerys T-cannula application. Complications were observed in 2% of the treated patients, which is a number presented also by international studies. CONCLUSION Tracheal resection is definitely an optimal solution for patients suffering from tracheal stenosis. As presented in our study, in the hands of experienced thoracic surgeons tracheal resections is a safe and final solution of tracheal stenosis. KEY WORDS trachea - stenosis resection.
Collapse
|
23
|
Borovec J, Cegan M, Mala K, Harmash N, Chramosta P, Kobierzycki C, Bobek V. Histopathological case report of high grade salivary duct carcinoma. Folia Histochem Cytobiol 2015; 53:342-5. [PMID: 26691893 DOI: 10.5603/fhc.a2015.0031] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Accepted: 12/14/2015] [Indexed: 11/25/2022] Open
Abstract
The case of a 39-year-old man with slowly growing mass in the superior part of left parotid region is described. Patient presented neurological symptoms including hypomobility of lower left eyelid and inability of complete closure of left side eyelids resulting in conjunctivitis and hyperlacrimation. Routine physical examination supported by image and laboratory tests was performed. Pathomorphological results of hematoxylin and eosin staining as well immunohistochemical examination in view of clinical presentation pointed to diagnosis of high grade salivary duct carcinoma. Rare incidence, histological view similar to breast cancer and body localization are sufficient reasons for further analyses and descriptions of this type of lesions.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Vladimir Bobek
- Department of Laboratory Genetics University Hospital Kralovske Vinohrady, Prague.
| |
Collapse
|
24
|
Bobek V, Majewski A, Kolostova K, Rzechonek A, Lischke R, Schutzner J, Kacprzak G. Intrapleural administration of DNase alone for pleural empyema. Int J Clin Exp Med 2015; 8:22011-22015. [PMID: 26885174 PMCID: PMC4724020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Accepted: 11/14/2015] [Indexed: 06/05/2023]
Abstract
INTRODUCTION Pleural empyema is a severe complication of various diseases. The essential is the inserting a drain into the pleural cavity and evacuation of the pus. Sometimes the pus is very thick and its evacuation and re-expansion of the lung is very difficult. METHODS We report a group of 10 patients with intrapleural administration of Pulmozyme (dornase alpha) in dosages of either 2.5 mg once or on two separate occasions. All of the patients had a chest tube inserted into the pleural cavity. Measurement of viscosity was done before and after the instillation of the dornase alpha. RESULTS In six patients dornase alfa was introduced into the pleural cavity once. Three of them received this on the 4th whilst the rest were treated with the agent on the 6th day. Four patients received the dornase alpha twice because of the small amount of drainage fluid after the previous instillation. Five patients were discharged from hospital with complete re-expansion of their lungs. Two patients were qualified for a surgical operation since the lung was trapped and did not re-expand. Three patients had to be discharged with a drain as a result of incomplete re-expansion of the lung. In all the patients the density of the pus after administering the dornase alpha decreased and the amount of the pus drainage increased. CONCLUSIONS Dornase alpha may be used in some patients with pleural empyema with good results.
Collapse
Affiliation(s)
- Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske VinohradyPrague, Czech Republic
- Department of Histology and Embryology, Wroclaw Medical UniversityWrocław, Poland
- 3rd Department of Surgery, First Faculty of Medicine Charles University in Prague and University Hospital MotolCzech Republic
| | - Andrzej Majewski
- Department of Thoracic Surgery, Nottingham City HospitalNottingham, UK
| | - Katarina Kolostova
- Department of Laboratory Genetics, University Hospital Kralovske VinohradyPrague, Czech Republic
| | - Adam Rzechonek
- Department of Thoracic Surgery, Wroclaw Medical UniversityWroclaw, Poland
- Wroclaw Thoracic Surgery Centre, Lower Silesian Centre of Lung DiseasesWroclaw, Poland
| | - Robert Lischke
- 3rd Department of Surgery, First Faculty of Medicine Charles University in Prague and University Hospital MotolCzech Republic
| | - Jan Schutzner
- 3rd Department of Surgery, First Faculty of Medicine Charles University in Prague and University Hospital MotolCzech Republic
| | - Grzegorz Kacprzak
- Department of Thoracic Surgery, Wroclaw Medical UniversityWroclaw, Poland
| |
Collapse
|
25
|
Kolostova K, Matkowski R, Jędryka M, Soter K, Cegan M, Pinkas M, Jakabova A, Pavlasek J, Spicka J, Bobek V. The added value of circulating tumor cells examination in ovarian cancer staging. Am J Cancer Res 2015; 5:3363-3375. [PMID: 26807317 PMCID: PMC4697683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Accepted: 08/31/2015] [Indexed: 06/05/2023] Open
Abstract
Delayed diagnosis of ovarian cancer (OC) is usually a cause of its high mortality. OC counts for one of the most aggressive gynecological malignancies. Noninvasive biomarkers may be used to help with diagnostic and treatment decisions in OC management. The incidence and clinical significance of occult OC cells (circulating tumor cells-CTCs) in the peripheral blood of patients with newly diagnosed or nondiagnosed OC at the time of surgical intervention were examined in our study. The objective of the study was to isolate and cultivate CTCs in OC patients (mainly stage IIIB-C) by a recently introduced size-based separation method (MetaCell(®)). CTCs were successfully isolated in patients with OC capturing cells with proliferation potential. The cells were enriched in good fitness, which enabled the short term in vitro culture of the CTCs. The CTCs may be used for further downstream applications (e.g. gene expression analysis) even if in the majority of the in vitro CTC cultures no confluence was reached. The CTCs were detected in 77 out of 118 patients (65.2%). CTC positivity was given to the relationship with different disease stage parameters with special focus on CA125 marker levels. The results show that the information on CTC presence may provide new and independent prognosis staging information to the patient description. Several interesting relationships of CA125, age and ascites presence are reported. As shown in our patient sample, patients with ascites tend to have higher CA125 levels, even if the CTCs were not found in the peripheral blood. It suggests that hematogenous dissemination is fully represented by the CTCs while lymphogenic dissemination is represented by elevated CA125. In this context, easy access to CTCs provided by the method applied in our study, both at the time of diagnosis and relapse, may become an increasingly valuable tool in future. This methodology may provide an opportunity for more personalized medicine where treatment for OC may be guided by information from an individual's CTC molecular profile.
Collapse
Affiliation(s)
- Katarina Kolostova
- Department of Cell and Molecular Biology, 3 Faculty of Medicine, Charles University PragueRuska 87, 100 97 Prague, Czech Republic
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 100 34 Prague, Czech Republic
| | - Rafał Matkowski
- Division of Surgical Oncology, Gynaecological Oncology, Chemotherapy and Department of Oncology, Wroclaw Medical UniversityPlac Hirszfelda 12, 53-413 Wrocław, Poland
- Lower Silesian Oncology CentreWroclaw, Plac Hirszfelda 12, 53-413 Wroclaw, Poland
| | - Marcin Jędryka
- Division of Surgical Oncology, Gynaecological Oncology, Chemotherapy and Department of Oncology, Wroclaw Medical UniversityPlac Hirszfelda 12, 53-413 Wrocław, Poland
- Lower Silesian Oncology CentreWroclaw, Plac Hirszfelda 12, 53-413 Wroclaw, Poland
| | - Katarzyna Soter
- Division of Surgical Oncology, Gynaecological Oncology, Chemotherapy and Department of Oncology, Wroclaw Medical UniversityPlac Hirszfelda 12, 53-413 Wrocław, Poland
| | - Martin Cegan
- Department of Cell and Molecular Biology, 3 Faculty of Medicine, Charles University PragueRuska 87, 100 97 Prague, Czech Republic
- Department of Pathology, Masaryk’s Hospital in Usti nad Labem, Krajska zdravotni a.s.Socialni pece 3316/12A, 40113 Usti nad Labem, Czech Republic
| | - Michael Pinkas
- Department of Cell and Molecular Biology, 3 Faculty of Medicine, Charles University PragueRuska 87, 100 97 Prague, Czech Republic
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 100 34 Prague, Czech Republic
| | - Anna Jakabova
- Department of Cell and Molecular Biology, 3 Faculty of Medicine, Charles University PragueRuska 87, 100 97 Prague, Czech Republic
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 100 34 Prague, Czech Republic
| | - Jiri Pavlasek
- Department of Gynecology and Obstetrics, University Hospital Kralovske VinohradySrobarova 50, 100 34 Prague, Czech Republic
| | - Jan Spicka
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 100 34 Prague, Czech Republic
| | - Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske VinohradySrobarova 50, 100 34 Prague, Czech Republic
- Department of Histology and Embryology, Wroclaw Medical UniversityWrocław, Poland
| |
Collapse
|
26
|
Bobek V, Matkowski R, Gürlich R, Grabowski K, Szelachowska J, Lischke R, Schützner J, Harustiak T, Pazdro A, Rzechonek A, Kolostova K. Cultivation of circulating tumor cells in esophageal cancer. Folia Histochem Cytobiol 2015; 52:171-7. [PMID: 25308732 DOI: 10.5603/fhc.2014.0020] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 09/01/2014] [Accepted: 09/09/2014] [Indexed: 01/28/2023] Open
Abstract
The presence of circulating tumor cells (CTCs) in patients with metastatic carcinoma is generally associated with poor clinical outcome. There have been many investigations showing a possible use of CTCs as minimally invasive predictive and prognostic biomarker in cancer medicine. In this report a size-based method (MetaCell®) for quick and easy enrichment and cultivation of CTCs is presented to enable possible CTCs use in esophageal cancer (EC) management. In total, 43 patients with diagnosed EC, 20 with adenocarcinoma (AdenoCa) and 23 with squamous cell carcinoma (SCC), were enrolled into the adaptive prospective-like study .All the patients were candidates for surgery. The CTCs were detected in 27 patients (62.8%), with a higher rate in adenocarcinoma (75%) than SCC (52%). Finally, there were 26 patients with resectable tumors exhibiting CTCs-positivity in 69.2% and 17 patients with non-resectable tumors with 41.7% CTCs-positivity. Interestingly, in the patients undergoing neoadjuvant therapy, the CTCs were detected at time of surgery in 55.5% (10/18). The overall size-based filtration approach enabled to isolate viable CTCs and evaluate to their cytomorphological features by means of vital fluorescent staining. The CTCs were cultured in vitro for further downstream applications including immunohistochemical analysis. This is the first report of the successful culturing of esophageal cancer CTCs. The detection of CTCs presence could help in the future to guide timing of surgical treatment in EC patients.
Collapse
Affiliation(s)
- Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic; Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland; 3rd Department of Surgery, 1st Faculty of Medicine Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Kolostova K, Spicka J, Matkowski R, Bobek V. Isolation, primary culture, morphological and molecular characterization of circulating tumor cells in gynecological cancers. Am J Transl Res 2015; 7:1203-1213. [PMID: 26328005 PMCID: PMC4548313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2015] [Accepted: 07/10/2015] [Indexed: 06/04/2023]
Abstract
The focus of the study was to implement a new workflow for circulating tumor cells (CTCs) characterization that would allow the analysis of CTCs on a cytomorphological and molecular level in patients with diagnosed gynecological cancer. Our findings may be useful in future cancer patient management. The study introduces a size-based enrichment (MetaCell(®)) method for the separation of viable CTCs, followed by CTCs culturing in vitro and gene expression characterization. It is based on the observation of CTCs and DTCs (Disseminated Tumor Cells) in several case studies of ovarian, endometrial and cervical cancer by means of cytomorphology and gene expression profiling. The viability of the enriched CTCs was estimated using vital and lethal fluorescence nuclear staining. This type of staining may be predictive for the success rate of subsequent CTC growth in vitro. To identify CTCs in the enriched CTC fraction, cytomorphological evaluations based on vital fluorescence staining were followed by gene expression analysis of tumor-associated (TA) genes. Cytokeratin expression (KRT7, KRT19) was analyzed in combination with MUC1, MUC16, CD24, CD44 and ALDH1. Gene expression analysis has shown that short-term in vitro culture enhanced the differentiation process of the captured CTCs growing on a membrane. On the other hand, redundant white blood cells captured on the membrane were eliminated during a short-term culture. The most frequently elevated genes in ovarian cancer (serous type) are EPCAM, KRT19 and MUC1. It has been demonstrated that CTC presence revealed by cytomorphological evaluation may be usefully complemented by TA-gene expression analysis, to increase the sensitivity of the analysis.
Collapse
Affiliation(s)
- Katarina Kolostova
- Department of Laboratory Genetics, Institute of Laboratory Diagnostics, University Hospital Kralovske VinohradySrobarova 50, Prague, Czech Republic
| | - Jan Spicka
- Department of Biochemistry, Institute of Laboratory Diagnostics, University Hospital Kralovske VinohradySrobarova 50, Prague, Czech Republic
| | - Rafal Matkowski
- Division of Surgical Oncology and Department of Oncology, Wroclaw Medical UniversityPlac Hirszfelda 12, 53-413 Wrocław, Poland
- Lower Silesian Oncology Centrepl. Hirszfelda 12, 53-413 Wroclaw, Poland
| | - Vladimir Bobek
- Department of Laboratory Genetics, Institute of Laboratory Diagnostics, University Hospital Kralovske VinohradySrobarova 50, Prague, Czech Republic
- 3rd Department of Surgery, First Faculty of Medicine Charles University in Prague and University Hospital MotolPrague, Czech Republic
- Department of Histology and Embryology, Wroclaw Medical UniversityChalubinskiego 6a, 50-368 Wroclaw, Poland
| |
Collapse
|
28
|
Bobek V, Gurlich R, Eliasova P, Kolostova K. Circulating tumor cells in pancreatic cancer patients: Enrichment and cultivation. World J Gastroenterol 2014; 20:17163-17170. [PMID: 25493031 PMCID: PMC4258587 DOI: 10.3748/wjg.v20.i45.17163] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2014] [Revised: 05/20/2014] [Accepted: 07/16/2014] [Indexed: 02/07/2023] Open
Abstract
AIM: To investigate the feasibility of separation and cultivation of circulating tumor cells (CTCs) in pancreatic cancer (PaC) using a filtration device.
METHODS: In total, 24 PaC patients who were candidates for surgical treatment were enrolled into the study. Peripheral blood samples were collected before an indicated surgery. For each patient, approximately 8 mL of venous blood was drawn from the antecubital veins. A new size-based separation MetaCell® technology was used for enrichment and cultivation of CTCs in vitro. (Separated CTCs were cultured on a membrane in FBS enriched RPMI media and observed by inverted microscope. The cultured cells were analyzed by means of histochemistry and immunohistochemistry using the specific antibodies to identify the cell origin.
RESULTS: CTCs were detected in 16 patients (66.7%) of the 24 evaluable patients. The CTC positivity did not reflect the disease stage, tumor size, or lymph node involvement. The same percentage of CTC positivity was observed in the metastatic and non-metastatic patients (66.7% vs 66.7%). We report a successful isolation of CTCs in PaC patients capturing proliferating cells. The cells were captured by a capillary action driven size-based filtration approach that enabled cells cultures from the viable CTCs to be unaffected by any antibodies or lysing solutions. The captured cancer cells displayed plasticity which enabled some cells to invade the separating membrane. Further, the cancer cells in the “bottom fraction”, may represent a more invasive CTC-fraction. The CTCs were cultured in vitro for further downstream applications.
CONCLUSION: The presented size-based filtration method enables culture of CTCs in vitro for possible downstream applications.
Collapse
|
29
|
Abstract
INTRODUCTION Results of clinical trials have demonstrated that circulating tumour cells (CTCs) are frequently detected in patients with urothelial tumours. The monitoring of CTCs has the potential to improve therapeutic management at an early stage and also to identify patients with increased risk of tumour progression or recurrence before the onset of clinically detected metastasis. In this study, we report a new effectively simplified methodology for a separation and in vitro culturing of viable CTCs from peripheral blood. METHOD We include patients diagnosed with 3 types of urothelial tumours (prostate cancer, urinary bladder cancer, and kidney cancer). A size-based separation method for viable CTC - enrichment from unclothed peripheral blood has been introduced (MetaCell, Ostrava, Czech Republic). The enriched CTCs fraction was cultured directly on the separation membrane, or transferred from the membrane and cultured on any plastic surface or a microscopic slide. RESULTS We report a successful application of a CTCs isolation procedure in patients with urothelial cancers. The CTCs captured on the membrane are enriched with a remarkable proliferation potential. This has enabled us to set up in vitro cell cultures from the viable CTCs unaffected by any fixation buffers, antibodies or lysing solutions. Next, the CTCs were cultured in vitro for a minimum of 10 to 14 days to enable further downstream analysis (e.g., immunohistochemistry). CONCLUSION We demonstrated an efficient CTCs capture platform, based on a cell size separation principle. Furthermore, we report an ability to culture the enriched cells - a critical requirement for post-isolation cellular analysis.
Collapse
Affiliation(s)
- Katarina Kolostova
- Department of Laboratory Genetics University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Martin Cegan
- Department of Pathology, Masaryk's hospital in Usti nad Labem, Krajska zdravotni, Usti nad Labem, Czech Republic
| | - Vladimir Bobek
- Department of Laboratory Genetics University Hospital Kralovske Vinohrady, Prague, Czech Republic; ; Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
| |
Collapse
|
30
|
Kolostova K, Hoffman RM, Maawy A, Zhang Y, Bobek V. Abstract 3071: Size-based isolation of circulating tumor cells (CTCs) in mouse tumor models. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-3071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
We report here isolation and cultivation of circulating tumor cells (CTCs) in five human epithelial cancers (lung, prostate, colon, pancreatic and breast cancer) implanted in nude mice. All of the cancer cells were labeled with green fluorescent protein (GFP) for detection. CTCs were isolated with an antigen-independent size-based separation device (MetaCell®, Metacell s.r.o., Ostrava, Czech Republic). We were able to capture on average more than 2 cells for each of above cancer types whereby the tumor has been implanted atleast 2 weeks before blood withdrawal. The number of CTC is dependent on the stage of tumor in animals. There was a very high heterogeneity of the CTCs with regard to cell size and cell phenotype including epithelial- and mesenchymal-like type cells in vitro. The development of a facile in vitro isolation and imaging technology for CTCs will enable deeper understanding of CTC biology.
Citation Format: Katarina Kolostova, Robert M. Hoffman, Ali Maawy, Yong Zhang, Vladimir Bobek. Size-based isolation of circulating tumor cells (CTCs) in mouse tumor models. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3071. doi:10.1158/1538-7445.AM2014-3071
Collapse
Affiliation(s)
- Katarina Kolostova
- 1Department of Tumor Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | | | - Ali Maawy
- 3Department of Surgery, University of California San Diego, San Diego, CA
| | | | - Vladimir Bobek
- 4Department of Surgery, University Hospital Kralovske Vinohrady, Prague, Czech Republic
| |
Collapse
|
31
|
Bobek V, Kolostova K. Abstract 3078: Isolation and in vitro culturing of human circulating tumor cells. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-3078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The CTC-enrichment based on the size of the cells, is addressing the problem of reduced EpCAM expression, but filtration shows relatively low sensitivity and specificity, because small CTCs may escape of the detection, whereas big leukocytes may contaminate population of CTCs Isolation by size of epithelial tumor cells is based on use of filters, which preferentially capture tumor cells bigger than 8 uM.
Our filtration device (MetaCell®, Metacell s.r.o., Ostrava, Czech Republic) isolates tumor cells by size from a blood sample up to 6 ml. Moreover immunocytochemistry and FISH assays can be performed on the filter. The protocol enables to isolate viable cells, allowing further in vitro experiments. Furthermore, tumor cells can be isolated without using an antibody-based approach, suggesting that the device can be used for the isolation of a large spectrum of tumor cells, including cell of non-epithelial origin.
We presented the successful isolation and cultivation of CTC/DTC of the following cancer: NSCLC, mesothelioma, oesophageal cancer, colorectal cancer, gastric cancer, pancreatic cancer, leiomyosarcoma, prostate cancer, malignant melanoma and renal cancer.
Citation Format: Vladimir Bobek, Katarina Kolostova. Isolation and in vitro culturing of human circulating tumor cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3078. doi:10.1158/1538-7445.AM2014-3078
Collapse
Affiliation(s)
- Vladimir Bobek
- 3rd Faculty of Medicine, Charles University Prague, Prague, Czech Republic
| | - Katarina Kolostova
- 3rd Faculty of Medicine, Charles University Prague, Prague, Czech Republic
| |
Collapse
|
32
|
Eliasova P, Kolostova K, Kobierzycki C, Bobek V. Clinical studies monitoring circulating and disseminated tumor cells in gastrointestinal cancers. Folia Histochem Cytobiol 2014; 51:265-77. [PMID: 24497131 DOI: 10.5603/fhc.2013.0037] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Accepted: 02/05/2014] [Indexed: 02/06/2023] Open
Abstract
Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) are responsible for the development of metastatic disease, and may also hold the key to determining tailored therapies of advanced cancer disease. Our review summarizes the prognostic significance of the detection of CTCs and DTCs in various gastrointestinal cancers with an overview of their possible use as prognostic biomarkers. This could be used inthe future as a starting point for new clinical trials focusing on the predictive potential of circulating and disseminated tumor cells.
Collapse
Affiliation(s)
| | | | | | - Vladimir Bobek
- Department of Tumor Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Surgery, Third Faculty of Medicine, Charles University and University Hospital, Kralovske Vinohrady, Prague, Czech Republic.
| |
Collapse
|
33
|
Cegan M, Kolostova K, Matkowski R, Broul M, Schraml J, Fiutowski M, Bobek V. In vitro culturing of viable circulating tumor cells of urinary bladder cancer. Int J Clin Exp Pathol 2014; 7:7164-71. [PMID: 25400813 PMCID: PMC4230057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 09/18/2014] [Indexed: 06/04/2023]
Abstract
OBJECTIVE Approximately one third of patients diagnosed with muscle-invasive urinary bladder cancer (UBC) have undetected metastases at the time of treatment of the primary tumor. Currently there are no reliable specific serum markers for monitoring and evaluating risk profiles of urothelial cancers. Several studies suggest that detection of circulating tumor cells (CTCs) may correlate with the disease status and prognosis at baseline and early in the treatment of cancers. In this study a new way of isolation and in vitro cultivation of CTCs of urinary bladder cancer was introduced. MATERIALS AND METHODS Peripheral blood (PB) samples from 53 patients who had undergone urological procedure were evaluated using the MetaCell device (MetaCell s.r.o., Ostrava, Czech Republic). The patients enrolled in the study were both oncological patients with UBC and non-oncological patients with inflammation (14 patients). The sensitivity and quantification of CTCs were evaluated. The separated CTCs were cultured in vitro. RESULTS 39 patients with confirmed UBC were enrolled in the study. CTCs were detected in 25 (64%) patients, and most of these patients had between 6 and 10 cells. The separated CTCs were successfully cultured in vitro. CONCLUSION CTCs were detected in a higher percentage of patients than in other studies. This paper describes the first successful culturing of human UBC cells. The MetaCell approach used in this study enabled the capture of viable intact virgin CTCs (virgin CTC) suitable for next in vitro culturing, single cell analysis or drug testing.
Collapse
Affiliation(s)
- Martin Cegan
- Department of Pathology, Masaryk’s Hospital in Usti Nad LabemKrajska Zdravotni a.s., Socialni Pece 3316, 12A40113 Usti Nad Labem, Czech Republic
| | - Katarina Kolostova
- Department of Laboratory Genetics University Hospital Kralovske VinohradySrobarova 50, 100 97 Prague, Czech Republic
| | - Rafal Matkowski
- Department of Oncology and Division of Oncological Surgery, Wroclaw Medical Universityul. Pasteura 1, 50-367 Wrocław, Poland
- Lower Silesian Oncology CentrePlac Hirszfelda 12, 53-413 Wrocław, Poland
| | - Marek Broul
- Department of Urology and Center of Robotic Surgery, Masaryk’s Hospital in Usti Nad LabemKrajska Zdravotni a.s., Socialni Pece 3316, 12A40113 Usti Nad Labem, Czech Republic
| | - Jan Schraml
- Department of Urology and Center of Robotic Surgery, Masaryk’s Hospital in Usti Nad LabemKrajska Zdravotni a.s., Socialni Pece 3316, 12A40113 Usti Nad Labem, Czech Republic
| | - Marek Fiutowski
- Department of Urology, Regional Specialistic Hospitalul. Kamienskiego 73a, 51-318 Wroclaw, Poland
| | - Vladimir Bobek
- Department of Laboratory Genetics University Hospital Kralovske VinohradySrobarova 50, 100 97 Prague, Czech Republic
- Department of Histology and Embryology, Wroclaw Medical UniversityChalubinskiego 6a, 50-368 Wroclaw, Poland
- Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol105 00 Prague, Czech Republic
| |
Collapse
|
34
|
Kolostova K, Zhang Y, Hoffman RM, Bobek V. In vitro culture and characterization of human lung cancer circulating tumor cells isolated by size exclusion from an orthotopic nude-mouse model expressing fluorescent protein. J Fluoresc 2014; 24:1531-6. [PMID: 25141982 PMCID: PMC4159578 DOI: 10.1007/s10895-014-1439-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Accepted: 08/11/2014] [Indexed: 12/15/2022]
Abstract
In the present study, we demonstrate an animal model and recently introduced size-based exclusion method for circulating tumor cells (CTCs) isolation. The methodology enables subsequent in vitro CTC-culture and characterization. Human lung cancer cell line H460, expressing red fluorescent protein (H460-RFP), was orthotopically implanted in nude mice. CTCs were isolated by a size-based filtration method and successfully cultured in vitro on the separating membrane (MetaCell®), analyzed by means of time-lapse imaging. The cultured CTCs were heterogeneous in size and morphology even though they originated from a single tumor. The outer CTC-membranes were blebbing in general. Abnormal mitosis resulting in three daughter cells was frequently observed. The expression of RFP ensured that the CTCs originated from lung tumor. These readily isolatable, identifiable and cultivable CTCs can be used to characterize individual patient cancers and for screening of more effective treatment.
Collapse
Affiliation(s)
- Katarina Kolostova
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 100 34 Prague, Czech Republic
| | | | - Robert M. Hoffman
- AntiCancer, Inc., San Diego, CA USA
- Department of Surgery, University of California, San Diego, CA USA
| | - Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 100 34 Prague, Czech Republic
- 3rd Department of Surgery First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic
- Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
| |
Collapse
|
35
|
Bobek V, Kolostova K, Kucera E. Circulating endometrial cells in peripheral blood. Eur J Obstet Gynecol Reprod Biol 2014; 181:267-74. [PMID: 25195200 DOI: 10.1016/j.ejogrb.2014.07.037] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Revised: 07/23/2014] [Accepted: 07/29/2014] [Indexed: 11/16/2022]
Abstract
OBJECTIVES Endometriosis is a common disorder amongst women of reproductive age. Despite extensive research, no reliable blood tests currently exist for the diagnosis of endometriosis STUDY DESIGN We report several new approaches enabling study of cell specific characteristic of endometrial cells, introducing enrichment and culturing of viable circulating endometrial cells (CECs) isolated from peripheral blood (PB) and peritoneal endometrial cells (PECs) from peritoneal washing (PW). Size-based enrichment method (MetaCell(®), Czech Republic) has been used for the filtration of PB and PW in patients with diagnosed endometriosis. RESULTS The PECs were found in the PW in all of the tested patients (n=17), but CECs) only in 23.5% (4/17) cases. Their endometrial origin has been proved by immunohistochemistry. PECs were successfully cultured in vitro directly on the separating membrane (9/17) exhibiting both endometrial cell phenotypes: stromal and glandular within the culture. CECs were successfully cultured in the two of the four positive cases, but in none of them confluence has been reached. The occurrence in CECs in PB is clear and very specific evidence of an active endometrial disease. CONCLUSIONS We demonstrated efficient, quick and user friendly endometrial cells capture platform based on a cell size. Furthermore, we demonstrated an ability to culture the captured cells, a critical requirement for post-isolation cellular analysis directed to better understanding of endometriosis pathogenesis.
Collapse
Affiliation(s)
- Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic; Department of Histology and Embryology, Wroclaw Medical University, Wrocław, Poland; 3rd Department of Surgery, First Faculty of Medicine Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
| | - Katarina Kolostova
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic; Department of Tumor Biology, 3rd Faculty of Medicine, Charles University Prague, Ruska 87, 100 97 Prague, Czech Republic
| | - Eduard Kucera
- Department of Gynecology and Obstetrics, 3(rd) Faculty of Medicine Charles University Prague and University Hospital Kralovske Vinohrady, Srobarova 50, 100 97 Prague, Czech Republic
| |
Collapse
|
36
|
Kolostova K, Broul M, Schraml J, Cegan M, Matkowski R, Fiutowski M, Bobek V. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score. Anticancer Res 2014; 34:3641-3646. [PMID: 24982381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The most promising near-term application of circulating tumor cells (CTCs) monitoring relates to the development of targeted cancer therapies, and the need to tailor such treatments to individual tumor characteristics. A high number of new innovative technologies to improve methods for detecting CTCs, with extraordinarily high sensitivity, have recently been presented. The identification and characterization of CTCs require extremely sensitive and specific methods that are able to isolate CTCs with the possibility of cultivation and downstream analysis of in vitro culture of separated CTCs. In this original research paper, we demonstrate that it is possible to isolate human CTCs from a patient with prostate cancer, with subsequent cultivation and proliferation in vitro. We show that the use of a filtration device implemented by MetaCell® can fulfil all the requirements mentioned above. Fifty-five patients with localized prostate cancer have so far been enrolled into the study. CTCs were detected in the blood samples of 28 (52%) out of the 55 patients. We report successful isolation of CTCs from patients with prostate cancer, capturing cells with a proliferative capacity in 18 (64.3%) out of the 28 CTC-positive patients. Direct correlation with Gleason score and T stage was not proven. The cells, captured by a size-based filtration approach, remain in a good state, unaffected by any antibodies or lysing solutions. During the filtration process, no interactions occurred between antibodies and antigens on the surface of CTCs. This biological interaction is specific for immunomagnetic methods. The MetaCell device provides the possibility of reaching virgin CTCs suitable for subsequent cultivation or single-cell analysis. This aspect will have an important impact on the future design of clinical trials testing new drugs against targets expressed on metastatic cancer cells. In addition to measurement of CTC counts, future trials with targeted therapies should also include the assessment of the specific therapeutic target on CTCs.
Collapse
Affiliation(s)
- Katarina Kolostova
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Marek Broul
- Clinic of Urology and Robotic Surgery, Masaryk's Hospital, Usti nad Labem, Czech Republic
| | - Jan Schraml
- Clinic of Urology and Robotic Surgery, Masaryk's Hospital, Usti nad Labem, Czech Republic
| | - Martin Cegan
- Department of Pathology, Masaryk's Hospital, Usti nad Labem, Czech Republic
| | - Rafal Matkowski
- Division of Oncology and Surgical Oncology, Wroclaw Medical University, Wroclaw, Poland Department of Surgical Oncology, Lower Silesian Oncology Centre, Wroclaw, Poland
| | - Marek Fiutowski
- Department of Urology, Regional Specialist Hospital, Wroclaw, Poland
| | - Vladimir Bobek
- Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Prague, Czech Republic Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
| |
Collapse
|
37
|
Bobek V, Lischke R, Schutzner J, Kolostova K. P-138 * CIRCULATING TUMOUR CELLS IN THORACIC MALIGNANCIES: SEPARATION AND CULTIVATION IN VITRO. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu167.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Bobek V, Kacprzak G, Rzechonek A, Kolostova K. Detection and cultivation of circulating tumor cells in malignant pleural mesothelioma. Anticancer Res 2014; 34:2565-2569. [PMID: 24778078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
UNLABELLED Malignant pleural mesothelioma (MPM) is an aggressive disease with very poor prognosis which tends to affect older patients. Progress in the management of this group of patients has been limited by the rarity of the disease and hence, difficulty in conducting randomized trials. The vast majority of cancer deaths occur due to metastasis of the primary tumor to distant sites via circulating tumor cells (CTCs) in the circulation. CTCs are extremely rare and limits in technology used to capture these cells hamper our complete understanding over the metastatic process. In the present study we present a new method for detection and cultivation of CTCs isolated from peripheral blood of MPM patients. PATIENTS AND METHODS Patients with diagnosed MPM were enrolled into this study. RESULTS A size-based separation method for viable CTC enrichment from unclothed peripheral blood has been introduced; MetaCell. The size-based enrichment process was based on filtration of peripheral blood (PB) through porous polycarbonate membrane. The separated CTCs are cultured on the membrane in vitro under standard cancer cell culture conditions and observed by an inverted microscope. CONCLUSION The reported methodology allows for quick and easy enrichment of CTCs and their cultivation. The cultivated cells can be used for next specification of gene expression and histological/biological specificity of concrete mesothelioma.
Collapse
Affiliation(s)
- Vladimir Bobek
- 3rd Faculty of Medicine Charles University Prague Department of Tumor Biology Ruska 87,100 97 Prague, Czech Republic.
| | | | | | | |
Collapse
|
39
|
Teyssler P, Kolostova K, Bobek V. The impact of platelet-rich plasma on chronic synovitis in hemophilia. Acta Orthop Belg 2014; 80:11-17. [PMID: 24873079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Untreated chronic haemophiliac synovitis leads to the development of haemophilic arthropathy (HA) by affecting the metabolism of chondrocytes. Symptoms are progressive and often surgical intervention is required to prevent total loss of joint function. The focus of our study was to influence the chronic haemophiliac synovitis by means of autologous platelet-rich plasma (PRP) injection. Six patients with hemophilia (PWH), aged between 9 and 45 and manifesting chronic synovitis of the ankle joint on one or on both sides (8 joints in total) were included into the PRP-study. The patients were classified depending on their joint status using the Hemophilia Joint Health Score (HJHS) prior to and again two months after treatment. Three to five ml of PRP was injected into the joint cavity within 30 seconds. In all of the tested PWH pain relief has been reported subjectively by means of the HJHS and VAS scoring systems, comparing the pain intensity before PRP injection and two months after. The difference of pain perception has been found statistically significant for the VAS-scores. Considering the objective synovitis signs shown on MRI before and after PRP injection we recorded a decrease in the volume of free synovial fluid after PRP. All of the tested patients reported benefit of the PRP therapy.
Collapse
|
40
|
Kacprzak G, Kolostova K, Kolodziej J, Pawlak I, Rzechonek A, Bobek V. Immunomagnetic detection of cancer cells in pleural effusion of generalized cancer. Folia Histochem Cytobiol 2013; 51:201-5. [PMID: 24203625 DOI: 10.5603/fhc.2013.0028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2012] [Revised: 03/18/2013] [Accepted: 08/21/2013] [Indexed: 11/25/2022] Open
Abstract
Malignant pleural effusions (MPE) are a common clinical problem in patients with neoplastic disease. Pleural fluid cytology is the simplest definitive method for obtaining a diagnosis of MPE. We describe a method that may increase the cancer cell detection rate using immunomagnetic separation in MPE. In comparison to standard MPE cytodiagnostic methods, we report a more streamlined method of isolation living cells that are able to proliferate. These captured cells can then be used for additional downstream analysis e.g. chemosensitivity testing. Several case studies of MPE diagnostics using immunomagnetic separation are presented in the following report. The immunomagnetic separation of cancer cells from MPE could be used for more accurate staging of patients with routine effusions.
Collapse
|
41
|
Affiliation(s)
- P. Teyssler
- Department of Tumor Biology; Third Faculty of Medicine; Charles University; Prague Czech Republic
- Clinic of Orthopedics and Traumatology of Children and Adults; Second Faculty of Medicine; Charles University and University Hospital Motol; Prague Czech Republic
| | - K. Kolostova
- Department of Tumor Biology; Third Faculty of Medicine; Charles University; Prague Czech Republic
| | - V. Bobek
- Department of Tumor Biology; Third Faculty of Medicine; Charles University; Prague Czech Republic
- Department of Surgery; Third Faculty of Medicine; Charles University and University Hospital Kralovske Vinohrady; Prague Czech Republic
| |
Collapse
|
42
|
Bobek V. Abstract 1464: In vitro culturing of CTCs/DTCs in personalized cancer management. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-1464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Subsequent detection, quantification and molecular characterization of CTCs has an enormous potential in numerous of oncology areas. But detection and isolation of CTCs is technically quite challenging. The whole dissemination process encompasses also individual tumor cells which are found in relatively big quantities in peritoneal washings (PW) and pleural effusions (PE), so called disseminated tumor cells (DTCs).
Thanks in vitro cultures of separated CTCs/DTCs we were able to introduce additional chemosensitivity testing for the purpose of individualized cancer treatment. We present an isolation and cultivation of CTC/DTC of non-small cell lung cancer and gastrointestinal cancers (esophageal cancer, colorectal cancer, gastric cancer, pancreatic cancer) describing cultivation methodology on patients case studies.
The cancer cells were separated from body fluids (PW, PE, blood) using the differences in size of cancer cells if compared to other nucleated cells detected in body cavities. After reaching the confluence the chemosensitivity of cell cultures has been tested by xCELLigence system (RTCA, Roche) for different concentrations of single cis-platinum, gemcitabine and fluorouracyl (incubation time 24-72 hours) or their combinations. The dynamic real-time cell growth monitoring enables parallel or sequential combinations of administered drugs with a direct outcome for patients care.
Conclusions: We assume that developing cultivation strategies for CTCs/DTCs could bring us closer to the definition of the CTC/DTC-function within the dissemination process with a perspective to use this knowledge in personalized cancer treatment.
Citation Format: Vladimir Bobek. In vitro culturing of CTCs/DTCs in personalized cancer management. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1464. doi:10.1158/1538-7445.AM2013-1464
Collapse
Affiliation(s)
- Vladimir Bobek
- 3rd Faculty of Medicine, Charles University Prague, Prague, Czech Republic
| |
Collapse
|
43
|
Teyssler P, Taborska K, Kolostova K, Bobek V. Radiosynoviorthesis in hemophilic joints with yttrium-90 citrate and rhenium-186 sulfide and long term results. Hell J Nucl Med 2013; 16:44-9. [PMID: 23529393 DOI: 10.1967/s002449910071] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 01/24/2013] [Accepted: 03/20/2013] [Indexed: 11/18/2022]
Abstract
Repeated bleeding in the joint cavities is the most annoying symptom and often has disabling effects in patients with hemophilia (PWH). Our aim was to study the effect of radiosynovectomy (RSO) with beta particle-emitting radiocolloids in the treatment of hemorhagic arthropathy. We have treated 22 joints from 18 patients with hemophilia A, from April 2008 to February 2012, 5 knees, 11 elbows and 6 ankles. Joints were divided into two Groups, those treated with yttrium-90-citrate ((90)Y-C) (5 knees, 2 of them twice)-Group I and those with rhenium-186-sulfide ((186)Re-S) (11 elbows, 1 of them treated twice and 6 ankles)-Group II. A total of 25 treatments. Follow-up period was 3 months, 1 year and 3 years. Results showed a favourable subjective and a better objective result in all 5 joints of Group I and in 15/17 joints of Group II, respectively. Follow-up after 3 months showed significant improvement in Hemophilia Join Health Score (HJHS) after 20 treatments and steady score after 5 treatments. After 1 year, 19 treated joints had improved for the first time, 3 remained steady and 3 were not examined. After 3 years, 9 treated joints were HJHS steady, while 16 were not examined. One year after treatment, 13/14 joints of patients, aged 6-23 years showed better HJHS score, while 9/11 joints of patients aged 26-51 years, showed better HJHS. Synovial membrane thickness as measured by MRI in 8 joints, before and 3 months after treatment was not related to prognosis. In conclusion, in a small group of hemophilic patients with hemorrhagic arthropathy treated with (90)Y-C and with (186)Re-S, our study showed good results irrespective of age in 22/25 treatments after 3 months or 1 year. The thickness of synovial membrane in the 8 joints studied was not related to prognosis.
Collapse
Affiliation(s)
- Petr Teyssler
- Department of Tumor Biology, 3rd Faculty of Medicine Charles University Prague, Ruska 87, 100 97 Prague, Czech Republic
| | | | | | | |
Collapse
|
44
|
Kacprzak G, Majewski A, Kolodziej J, Rzechonek A, Gürlich R, Bobek V. New therapy of pleural empyema by deoxyribonuclease. Braz J Infect Dis 2013; 17:90-3. [PMID: 23332886 PMCID: PMC9427380 DOI: 10.1016/j.bjid.2012.08.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2012] [Accepted: 08/05/2012] [Indexed: 11/30/2022] Open
Abstract
Empyema is a severe complication of different diseases and traumas. Management of this complication is difficult and should comprise general and local procedures. The general procedure is mainly based on administering wide-spectrum antibiotics. Local management depends on patient general condition, but in all cases the essential procedure is to insert a drain into the pleural cavity and to evacuate the pus. Sometimes pus is very thick and its evacuation and following re-expansion of the lung is rather impossible. In these patients surgical intervention is needed. The use of intrapleural enzymes to support the drainage was first described in 1949 by Tillett and Sherry using a mixture of streptokinase and streptococcal deoxyribonuclease. Nowadays, purified streptokinase has come into widespread use, but recent studies reported no streptokinase effect on pus viscosity. On the other side, deoxyribonuclease reduces pus viscosity and may be more useful in treatment. We report two cases of intrapleural administration of Pulmozyme (alfa dornase – deoxyribonuclease (HOFFMANN-LA ROCHE AG) in dosage 2 × 2.5 mg with a significant improvement caused by changes in pus viscosity.
Collapse
Affiliation(s)
- Grzegorz Kacprzak
- Wroclaw Thoracic Surgery Centre, Department of Thoracic Surgery of Lower Silesian Centre, Department of Thoracic Surgery of Medical University Wroclaw, Poland
| | - Andrzej Majewski
- Wroclaw Thoracic Surgery Centre, Department of Thoracic Surgery of Lower Silesian Centre, Department of Thoracic Surgery of Medical University Wroclaw, Poland
- Department of Thoracic Surgery, Nottingham City Hospital, Nottingham, UK
| | - Jerzy Kolodziej
- Wroclaw Thoracic Surgery Centre, Department of Thoracic Surgery of Lower Silesian Centre, Department of Thoracic Surgery of Medical University Wroclaw, Poland
| | - Adam Rzechonek
- Wroclaw Thoracic Surgery Centre, Department of Thoracic Surgery of Lower Silesian Centre, Department of Thoracic Surgery of Medical University Wroclaw, Poland
| | - Robert Gürlich
- Department of Surgery, 3rd Faculty of Medicine Charles University and Hospital Kralovske Vinohrady Prague, Czech Republic
| | - Vladimir Bobek
- Wroclaw Thoracic Surgery Centre, Department of Thoracic Surgery of Lower Silesian Centre, Department of Thoracic Surgery of Medical University Wroclaw, Poland
- Department of Surgery, 3rd Faculty of Medicine Charles University and Hospital Kralovske Vinohrady Prague, Czech Republic
- Department of Tumor Biology, 3rd Faculty of Medicine Charles University Prague, Czech Republic
- Corresponding author at: 3rd Faculty of Medicine Charles University Prague, Department of Tumor Biology, Ruska 87, 100 97 Prague, Czech Republic. Tel.: +420 267 102 108; fax: +420 267 102 650.
| |
Collapse
|
45
|
Teyssler P, Trč T, Kološtová K, Bobek V. [Recurrent intra-articular bleeding episodes in haemophiliacs. Treatment outcomes in the patients at the university hospital motol in 1985-2005]. Acta Chir Orthop Traumatol Cech 2013; 80:396-399. [PMID: 24750967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
PURPOSE OF THE STUDY Chronic synovitis is a common finding in people with haemophilia. It regularly appears after recurrent episodes of intra-articular bleeding. The bleeding originates from the subsynovial venous plexus underlying the capsule where a lack of thromboplastic activity has been demonstrated. Therefore, the changed synovium appears to be a treatment target. There are several methods which can be used to remove the synovial layer from the joint. The aim of our study was to asses the efficacy of different treatment approaches used in a group of haemophiliacs between 1985 and 2005 in our hospital. MATERIAL AND METHODS A group of 30 patients with bleeding disorders was evaluated in the study. There were 29 men with haemophilia and one woman with von Wilebrandt factor deficiency. Their age ranged from 6 to 18 (median 13) years. They underwent a total of 68 interventions including surgical synovectomy (n=28), radionuclide synovectomy (n=33) and corticosteroid instillation (n=7). The necessity of a repeat intervention was used as a criterion of successful treatment. RESULTS In the group of surgical synovectomies, 22% of the patients required repeat operations, in the group of radiation synovectomy, this was 9% and, in the group treated with corticosteroids, this was 43%. The average hospitalisation time was 50 days for surgical procedures (19-133 days) and 7 days for radiation synovectomy procedures (4-13 days). DISCUSSION In 1994 Merchan presented seven excellent or good results in a group of 10 knees evaluated 1 year after treatment with methylprednisolone. Six years later he reported that "five years after completion of treatment, all results of the observed patients were poor". Generally, corticosteroids will reduce synovitis in the majority of patients but the effect is temporary. A complete remission is a very rare situation under corticosteroid treatment. The experience with surgical synovectomies is not recent and this method is described as carrying a high risk of complications and requiring a high amount of coagulating factor consumption. There are several recent reports on the application of Yttrium-90: in Madrid they evaluated treated joints (knees, ankles and elbows, n = 66) in 44 patients aged from 9 to 39 years. The results were good in less than half of the knees and ankles. The treatment of elbows was more successful. It was recommended to perform synoviorthesis at the early stages of synovitis. In Israel, they reported that a decrease in the number of bleeding episodes was achieved in 80% of 115 patients treated with Yttrium-90; in 15% of them, bleeding in the treated joints stopped completely. In Izmir, Yttrium was used in the treatment of knees, elbows, ankles and also shoulders in children and young adults (3-25 years). The method was found to be safe and effective. Brazilian authors have experience with the treatment of knees, ankles, elbows and shoulders too; they have concluded that this method represents an important resource for the treatment of chronic haemophilic synovitis and markedly reduces joint bleeding frequency and pain, irrespective of the radiographic stage and inhibitor status. While the European Association of Nuclear Medicine (EANM) recommend using 186Re-sulfide for treatment in medium-sized joints, Chinese authors have published a study comparing the effect of using three different doses of 186Re-sulfide in the treatment of chronic synovitis in knees. Their patients have received an amount of radionuclide according to the thickness of their synovial layer measured on MRI, with the result that 22 patients exhibited significant reduction in synovial thickness. A reduction in the number of bleeding episodes was reached in 71% of the patients within an 18-month period. No significant differences were found among the groups receiving different radioactivity doses. In Turkey, 35 elbows, 26 ankles and two shoulders in 49 patients aged between 3 and 30 years were treated with 186Re. The patients were followed up from 6 months to 3 years. At 6 months after the procedure, 81% of the elbows and 86% of the ankles with grade II synovitis were free from bleeding, as well as 53% and 44% of the elbows and ankles with grade III synovitis, respectively. CONCLUSIONS Radiation synovectomy appears to be the method of choice in the treatment of recurrent bleeding in the joint cavity in people with haemophilia. The efficacy of surgical synovectomy is lower in comparison with radiation synovectomy. Risks associated with surgery and anaesthesia, the need of hospitalisation and a prolonged period of rehabilitation are bothering. On the contrary, the application of corticosteroids cannot be recommended as a good method to treat recurrent haemarthroses.
Collapse
Affiliation(s)
- P Teyssler
- Klinika dětské a dospělé ortopedie a traumatologie 2. LF UK a FN v Motole, Praha
| | | | | | | |
Collapse
|
46
|
Menen R, Pinney E, Kolostova K, Bobek V, Suetsugu A, Zhang N, Hoffman RM. Determining the metastatic potential of circulating tumor cells. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e21051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21051 Background: Knowledge of the metastatic potential of circulating tumor cells would be useful for cancer prognosis and also be a rationale for targeting metastatic CTCs for therapy. Methods: Using immunomagnetic beads, CTCs were rapidly isolated from the circulation of mice orthotopically implanted with human PC-3 prostate cancer cells stably expressing green fluorescent protein (GFP). The PC-3–GFP CTCs were then expanded in culture in parallel with the parental PC-3–GFP cell line. Both cell types were then inoculated onto the chorioallentoic membrane (CAM) of chick embryos. Eight days later, embryos were harvested and the brains were processed for frozen sections. The IV-100 intravital laser scanning microscope enabled rapid identification of fluorescent metastatic foci within the chick embryonic brain. Results: Inoculation of embryos with PC-3–GFP CTCs resulted in a 3 to 10-fold increase in brain metastasis when compared to those with the parental PC-3–GFP cells (p<0.05 in all animals). Thus, PC-3–GFP CTCs have increased metastatic potential compared to their parental counterparts. Conclusions: The chick embryo represents a rapid, sensitive, imageable assay of metastatic potential for CTCs. The chick embryo assay has future clinical application for individualizing patient therapy based on the metastatic profile of their CTCs.
Collapse
Affiliation(s)
| | | | - Katarina Kolostova
- Department of Gynecology and Obstetrics, Division of Tumor Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Vladimir Bobek
- Department of Gynecology and Obstetrics, Division of Tumor Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | | | | | - Robert M. Hoffman
- AntiCancer, Inc. and University of California San Diego, San Diego, CA
| |
Collapse
|
47
|
Bobek V. Anticoagulant and Fibrinolytic Drugs Possible Agents in Treatment of Lung Cancer? Anticancer Agents Med Chem 2012; 12:580-8. [DOI: 10.2174/187152012800617687] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2011] [Revised: 01/17/2012] [Accepted: 01/19/2012] [Indexed: 11/22/2022]
|
48
|
Menen R, Pinney E, Hassanein MK, Kolostova K, Bobek V, Suetsugu A, Zhang N, Bouvet M, Naughton GK, Hoffman RM. Inhibition of metastasis of circulating human prostate cancer cells in the chick embryo by an extracellular matrix produced by foreskin fibroblasts in culture. Anticancer Res 2012; 32:1573-1577. [PMID: 22593434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
We have previously demonstrated the increased metastatic potential of human prostate cancer circulating tumor cells (CTC), compared to their parental cells, in both orthotopic mouse models and the chick embryo model. In the current study, we asked whether an extracellular matrix (ECM), produced by human foreskin fibroblasts in culture, could inhibit PC-3 human prostate cancer CTC metastasis in the chick embryo model. The chorioallantoic membranes (CAM) of 18 chicken embryos were inoculated with either PC-3 human prostate cancer cells or PC-3 CTCs, both stably expressing green fluorescent protein (GFP). Embryos were divided into six groups: PC-3 parental-cell control; PC-3 plus soluble ECM; PC-3 parental cells plus semi-solid ECM; PC-3 CTC control; PC-3 CTC plus soluble ECM, and PC-3 CTC plus semi-solid ECM. Twelve hours following inoculation of the cells, a single dose of 100 μl of either soluble or semi-solid ECM was added to the appropriate group. Embryo brains were removed on day 8 post-inoculation, and were processed for cryosectioning. Imaging was performed on the cryosections using a scanning laser microscope in order to count metastatic foci. PC-3 controls had an average of 11.1 metastatic foci compared to 2.55 in the PC-3 plus soluble ECM group and 2.76 (p<0.0001) in the PC-3 plus semi-solid ECM group (p<0.0001). ECM treatment had even greater efficacy on the CTC cells, with an average of 30.9 metastatic foci in the CTC controls compared to 4.38 in the CTC plus soluble ECM group (p<0.0001) and 4.18 in the CTC plus semi-solid ECM group (p<0.0001). The results demonstrate that reduction of CTC metastatic potential is possible, in this case with an ECM produced by human foreskin fibroblasts in culture.
Collapse
Affiliation(s)
- Rhiana Menen
- AntiCancer Inc., 7917 Ostrow Street, San Diego, CA 92111, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Libalova P, Vernerova Z, Hubickova-Heringova L, Pinterova D, Kolostova K, Bobek V, Tikovsky K, Housa D, Kubecova M, Pecen L, Svoboda B. heterogeneity of dna ploidy in endometrial carcinoma: comparison of different tissue samples obtained during diagnosis and treatment. In Vivo 2012; 26:473-480. [PMID: 22523302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
AIM Comparison of DNA ploidy status of different tumour tissue samples (fresh/frozen vs. paraffin-embedded; curettage vs. hysterectomy samples) obtained during diagnosis and treatment of patients with endometrial carcinoma. PATIENTS AND METHODS DNA ploidy status and conventional prognostic parameters were recorded for 74 patients with endometrial carcinoma prospectively. RESULTS In 59 (79.7%) patients the DNA status was described as diploid in all analyzed tissue samples. The remaining 15 (20.3%) cases were described as DNA aneuploid in at least one of the corresponding tissue samples. The concordance between DNA ploidy status in fresh vs. paraffin-embedded hysterectomy samples as well as curettage vs. hysterectomy paraffin-embedded samples was high (kappa coefficient κ=0.6348, 95% confidence interval CI=0.3673-0.9023, and p=0.6408, 95% CI=0.3977-0.8838), however, the methods are not interchangeable. CONCLUSION The DNA ploidy discordance observed in our study group seems to document intratumoral heterogeneity that should be expected when applying DNA ploidy status in the clinical management of endometrial carcinoma.
Collapse
Affiliation(s)
- Pavla Libalova
- Department of Gynaecology and Obstetrics, Third Faculty of Medicine of Charles University and The Kralovske Vinohrady University Hospital, Ruska 87, 100 34 Prague, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Bobek V, Hoffman RM, Kolostova K. Site-specific cytomorphology of disseminated PC-3 prostate cancer cells visualized in vivo with fluorescent proteins. Diagn Cytopathol 2012; 41:413-7. [PMID: 22508666 DOI: 10.1002/dc.22843] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2011] [Accepted: 01/11/2012] [Indexed: 12/13/2022]
Abstract
Circulating tumor cells (CTC) may reach multiple organ sites. However, CTC seeding and growth in distant organs is not random. Each metastatic site may contain a specific subpopulation of the original metastatic tumor capable of growing at that site. The fluorescent orthotopic prostate cancer model (PC-3-GFP) model was used for immunomagnetic capture of CTC. The captured CTC were efficiently cultivated in vitro. PC-3-GFP cells were also isolated from various metastatic sites, grown in vitro and examined under fluorescence microscopy. The differential morphology was compared of primary tumor cells, CTC and disseminated (DTC) from multiple metastatic sites, from nude mice with orthotopic PC-3-GFP. The cultured captured CTC and DTC from various organs have distinctive morphologies. Distinct cancer cell morphologies were observed at different metastatic sites as well as among CTC. The distinct morphologies were maintained during in vitro culture. The results demonstrate extensive tumor heterogeneity that could account for the widely different behavior of cancer cells in a single tumor. Further hetereogeneity testing would be a big promise for personalizing the cancer treatment in the future.
Collapse
Affiliation(s)
- Vladimir Bobek
- Department of Tumor Biology, Third Faculty of Medicine, Charles University, Prague 10010, Czech Republic.
| | | | | |
Collapse
|